[CAS NO. 180288-69-1] Trastuzumab
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [180288-69-1]
Store
Catalog
HY-P9907
Brand
MCE
CAS
180288-69-1
DESCRIPTION [180288-69-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 145531.50 |
| Molecular Formula | C6470H10012N1726O2013S42 |
| SMILES | [Trastuzumab] |
For research use only. We do not sell to patients.
14 Publications Citing Use of MCE
- [1]Signal Transduct Target Ther. 2020 Sep 14;5(1):200.
- [2]Nat Commun. 2020 Feb 26;11(1):1049.
- [3]Cancer Lett. 2020 Apr 10;475:53-64.
- [4]Elife. 2019 Jun 7;8:e46983.
- [5]J Exp Clin Cancer Res. 2019 May 22;38(1):214.
- [6]Anal Chim Acta. 2021, 338306.
- [7]Biomed Pharmacother. June 2022, 113051.
- [8]Nanomaterials. 2021, 11(12), 3181.
- [9]Breast Cancer Res Treat. 2021 Apr 27.
- [10]Diagnostics (Basel). 2022, 12(3), 591.
- [11]Biochem Bioph Res Co. 2020 Dec 10;533(3):533-539.
- [12]University of Washington. Department of Mechanical Engineering. 2021 Nov.
- [13]Patent. US20190151462A1
- [14]Biochemistry, Molecular Bio, and Biophysics. University of Minnesota. 2019 Feb.
Summary
IC50 & Target
|
HER2 |
In Vitro
Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes are observed in vitro as a consequence of Trastuzumab binding to HER2-overexpressing cells. Interaction of Trastuzumab with the human immune system via its human immunoglobulin G1 Fc domain may potentiate its antitumor activities. in vitro studies demonstrate that Trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets [1] . Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane portion of the extracellular domain of the HER2 receptor and that prevent the activation of its intracellular tyrosine kinase. Trastuzumab recruits immune effector cells that are responsible for antibody-dependent cytotoxicity [2] . The presence of Trastuzumab IgG significantly increases killing of all breast cancer cell lines. The ADCC activity of PBMCs evoked by Trastuzumab is equally strong against Trastuzumab-sensitive (SKBR-3) or Trastuzumab-resistant (JIMT-1) breast cancer cells, with dose-dependent cell death reaching 50–60% killing at an effector/target ratio of 60:1 [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Trastuzumab treatment of mouse xenograft models results in marked suppression of tumor growth. When given in combination with standard cytotoxic chemotherapeutic agents, Trastuzumab treatment generally results in statistically superior antitumor efficacy compared with either agent given alone [1] . Trastuzumab causes a significant growth inhibition of the outgrowth of macroscopic JIMT-1 xenograft tumors in both nude and SCID mice [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01235897 | University of California, San Francisco|Merck Sharp & Dohme LLC |
Advanced Solid Tumors|Tumors|Cancer
|
March 2011 | Phase 1 |
| NCT00453635 | Hellenic Oncology Research Group|University Hospital of Crete |
Breast Cancer
|
December 2003 | Phase 2 |
| NCT02721641 | Hoffmann-La Roche |
Neoplasms
|
June 1999 | Phase 3 |
| NCT00404066 | George Albert Fisher|GlaxoSmithKline|Sanofi|Stanford University |
Breast Cancer|Metastatic Breast Cancer
|
October 2006 | Phase 2 |
| NCT05376878 | City of Hope Medical Center|National Cancer Institute (NCI) |
Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Brain
|
October 16, 2022 | Phase 4 |
| NCT01873833 | University of Southern California|National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
July 29, 2013 | Phase 2 |
| NCT01423123 | NSABP Foundation Inc|Pfizer |
Breast Cancer
|
May 2011 | Phase 1 |
| NCT01875666 | UNC Lineberger Comprehensive Cancer Center|Genentech, Inc.|Susan G. Komen Breast Cancer Foundation|GlaxoSmithKline |
Breast Neoplasms
|
August 5, 2013 | Early Phase 1 |
| NCT00482391 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Dana-Farber Cancer Institute|GlaxoSmithKline |
Breast Cancer
|
March 2007 | Phase 2 |
| NCT04609540 | Shandong Cancer Hospital and Institute |
HER2-positive Breast Cancer|Metastatic Breast Cancer
|
January 1, 2021 | |
| NCT01603264 | Pfizer |
Healthy
|
May 2012 | Phase 1 |
| NCT00963547 | Merck Sharp & Dohme LLC |
Advanced Solid Tumors|Breast Cancer
|
September 15, 2009 | Phase 1 |
| NCT00068341 | Jonsson Comprehensive Cancer Center|Aventis Pharmaceuticals|Genentech, Inc. |
Breast Cancer
|
July 2003 | Phase 2 |
| NCT02057133 | Eli Lilly and Company |
Breast Neoplasms
|
March 10, 2014 | Phase 1 |
| NCT01975142 | Institut Curie |
Metastatic Breast Cancer, HER2 Negative Primary Tumor
|
November 7, 2013 | Phase 2 |
| NCT04993014 | AC Camargo Cancer Center |
Breast Neoplasms|HER2-positive Breast Cancer|Circulating Tumor Cell
|
March 1, 2021 | Phase 2 |
| NCT00847171 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Breast Cancer
|
December 2008 | Phase 2 |
| NCT00136539 | Harold J. Burstein, MD, PhD|Dana-Farber Cancer Institute|Genentech, Inc.|Bristol-Myers Squibb|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Harvard Vanguard Medical Associates|Brigham and Women´s Hospital |
Breast Cancer
|
March 1999 | Phase 2 |
| NCT04721977 | Merck Sharp & Dohme LLC |
Breast Cancer
|
April 8, 2021 | Phase 2 |
| NCT04281576 | NovoCure GmbH|Zai Lab (Shanghai) Co., Ltd.|NovoCure Ltd. |
Gastric Cancer|GastroEsophageal Cancer
|
December 19, 2019 | Not Applicable |
| NCT05504720 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest|Merck Sharp & Dohme LLC|Organon Healthcare GmbH |
Esophagogastric Adenocarcinoma
|
October 2022 | Phase 2 |
| NCT04917900 | West China Hospital |
Breast Cancer
|
December 1, 2020 | Phase 2 |
| NCT01026142 | Hoffmann-La Roche |
Breast Cancer
|
January 26, 2010 | Phase 3 |
| NCT03161353 | MedSIR |
Breast Cancer
|
June 26, 2017 | Phase 2 |
| NCT02291289 | Hoffmann-La Roche |
Colorectal Cancer
|
April 17, 2015 | Phase 2 |
| NCT04285671 | Jonsson Comprehensive Cancer Center|Eli Lilly and Company|Genentech, Inc. |
Metastatic Lung Non-Small Cell Carcinoma|Refractory Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8
|
January 29, 2021 | Phase 1|Phase 2 |
| NCT00084513 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
August 2004 | Phase 1 |
| NCT04042701 | Daiichi Sankyo, Inc.|AstraZeneca UK Limited|Merck Sharp & Dohme LLC |
Breast Cancer|Non-small Cell Lung Carcinoma
|
February 10, 2020 | Phase 1 |
| NCT00014430 | Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
November 1999 | Phase 1 |
| NCT01912963 | Dana-Farber Cancer Institute|Eisai Inc.|Genentech, Inc. |
HER2-positive Breast Cancer|Metastatic Breast Cancer
|
September 2013 | Phase 2 |
| NCT03112590 | H. Lee Moffitt Cancer Center and Research Institute|Horizon Pharma Ireland, Ltd., Dublin Ireland |
Breast Cancer|Breast Cancer, Male|Breast Cancer Female|HER2-positive Breast Cancer
|
June 23, 2017 | Phase 1|Phase 2 |
| NCT00545688 | Hoffmann-La Roche |
Breast Cancer
|
June 26, 2006 | Phase 2 |
| NCT03989037 | Shanghai Institute Of Biological Products|Fudan University |
HER2-positive Early Breast Cancer
|
June 30, 2019 | Phase 3 |
| NCT00401427 | National Cancer Institute, Naples |
Metastatic Breast Cancer
|
November 2002 | Phase 2 |
| NCT00770809 | National Cancer Institute (NCI) |
Male Breast Carcinoma|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7
|
December 1, 2008 | Phase 3 |
| NCT05474690 | Henan Cancer Hospital |
Breast Cancer|HER2-positive Breast Cancer
|
May 11, 2022 | Phase 3 |
| NCT00679211 | Genentech, Inc. |
Metastatic Breast Cancer
|
August 2008 | Phase 2 |
| NCT00736970 | Merck Sharp & Dohme LLC |
Breast Cancer|Breast Neoplasms
|
July 2008 | Phase 2 |
| NCT04188548 | Eli Lilly and Company |
Breast Cancer|Advanced Breast Cancer|Metastatic Breast Cancer|Endometrial Cancer
|
December 10, 2019 | Phase 1 |
| NCT01084863 | Celltrion |
Metastatic Breast Cancer
|
February 2010 | Phase 1|Phase 2 |
| NCT00448279 | Hoffmann-La Roche |
Breast Cancer
|
April 2007 | Phase 3 |
| NCT00485979 | Sanofi |
Breast Neoplasms
|
June 2007 | Phase 2 |
| NCT01196052 | Hoffmann-La Roche |
Breast Cancer
|
October 2010 | Phase 2 |
| NCT04430738 | Seagen Inc. |
Colorectal Carcinoma|Gastric Adenocarcinoma|GEJ Adenocarcinoma|Esophageal Adenocarcinoma|Cholangiocarcinoma|Gallbladder Carcinoma
|
September 15, 2020 | Phase 1|Phase 2 |
| NCT03505710 | Daiichi Sankyo, Inc.|Daiichi Sankyo Co., Ltd.|AstraZeneca |
Non-Small Cell Lung Cancer
|
May 21, 2018 | Phase 2 |
| NCT00006110 | UNC Lineberger Comprehensive Cancer Center |
Breast Cancer
|
December 1998 | Phase 2 |
| NCT02624973 | Haukeland University Hospital|Helse Vest|Pfizer|AstraZeneca |
Breast Cancer
|
April 15, 2016 | Phase 2 |
| NCT03180242 | EirGenix, Inc. |
Healthy
|
March 22, 2016 | Phase 1 |
| NCT01926886 | Hoffmann-La Roche |
Breast Cancer
|
November 19, 2013 | Phase 3 |
| NCT04962425 | Peking University Third Hospital |
Cardiac Toxicity|Antitumor Drugs|Breast Cancer
|
January 8, 2021 | |
| NCT00005033 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Sarcoma
|
December 1999 | Phase 2 |
| NCT01104571 | Institute of Cancer Research, United Kingdom|University of Manchester|Manchester University NHS Foundation Trust|Cancer Research UK|Novartis |
Breast Cancer
|
April 2010 | Phase 3 |
| NCT04509596 | Dizal Pharmaceuticals |
Breast Cancer Metastatic
|
September 21, 2020 | Phase 1 |
| NCT05480384 | Brown University|AstraZeneca |
Esophageal Adenocarcinoma|Esophageal Cancer|HER-2 Protein Overexpression|Gastroesophageal-junction Cancer
|
November 2022 | Phase 2 |
| NCT00613847 | Memorial Sloan Kettering Cancer Center |
Solid Tumors
|
October 2006 | Phase 1 |
| NCT00515411 | Memorial Sloan Kettering Cancer Center|Sanofi|Roche-Genentech|City of Hope National Medical Center|Piedmont Hospital Research Institute|Medical College of Wisconsin|Queens Health Network|Weill Medical College of Cornell University|Memorial Cancer Institute, Florida|University of Pittsburgh|Long Island Jewish Medical Center|Nebraska Cancer Specialists Methodist Estabrook Cancer Center |
Gastroesophageal Junction Adenocarcinoma|Gastric Cancer
|
October 23, 2006 | Phase 2 |
| NCT01526369 | Cancer Trials Ireland |
Metastatic Breast Cancer
|
January 2012 | Phase 3 |
| NCT01705340 | National Cancer Institute (NCI) |
Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer
|
September 2012 | Phase 1 |
| NCT04088110 | Fuzhou General Hospital |
Breast Cancer Female|HER2-positive Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|Metastatic Breast Cancer|Breast Diseases|Hormone Receptor Positive Tumor
|
November 2019 | Phase 2 |
| NCT03448042 | Genentech, Inc. |
Solid Tumors
|
June 6, 2018 | Phase 1 |
| NCT02530424 | Fondazione Michelangelo |
Breast Neoplasms
|
May 2015 | Phase 2 |
| NCT03738553 | University of Washington |
HER2-positive Breast Cancer
|
August 2013 | |
| NCT04960943 | Fudan University |
Gastrointestinal Tumor|Effect of Drug
|
February 1, 2020 | Phase 2 |
| NCT05572645 | Fudan University |
Breast Cancer
|
October 1, 2022 | |
| NCT00295893 | City of Hope Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
September 14, 2005 | Phase 2 |
| NCT01764022 | Biocad |
Human Epithelial Receptor (HER)-2 Positive Breast Cancer
|
October 2012 | Phase 3 |
| NCT00726180 | University of Michigan Rogel Cancer Center |
Breast Cancer
|
July 2008 | Phase 1|Phase 2 |
| NCT00191373 | Eli Lilly and Company |
Breast Neoplasms|Cancer of the Breast|Breast Cancer
|
March 2002 | Phase 2 |
| NCT00024154 | National Cancer Institute (NCI) |
Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
February 2002 | Phase 2 |
| NCT02205047 | European Organisation for Research and Treatment of Cancer - EORTC |
Malignant Neoplasm of Stomach|Malignant Neoplasm of Cardio-esophageal Junction of Stomach|Epidermal Growth Factor Receptor (EGFR) Protein Overexpression
|
July 15, 2015 | Phase 2 |
| NCT00367471 | Novartis Pharmaceuticals|Novartis |
Neoplasms, Breast
|
December 7, 2006 | Phase 1 |
| NCT01387295 | Dorte Nielsen|Herlev Hospital |
Metastatic Breast Cancer|Liver Metastases
|
April 2010 | Phase 2 |
| NCT00821886 | SCRI Development Innovations, LLC|Bristol-Myers Squibb|Genentech, Inc. |
Breast Cancer
|
February 2009 | Phase 2 |
| NCT04680442 | Population Health Research Institute |
Breast Cancer|Heart Failure
|
July 1, 2021 | Phase 2 |
| NCT05323955 | Carey Anders, M.D.|Seagen Inc.|Duke University |
Brain Metastases|Human Epidermal Growth Factor 2 Positive Carcinoma of Breast|Advanced Breast Cancer
|
September 1, 2022 | Phase 2 |
| NCT04120246 | University of Washington|Veana Therapeutics, Inc. |
Anatomic Stage IV Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Metastatic Breast Carcinoma|Refractory Breast Carcinoma
|
April 8, 2020 | Phase 1 |
| NCT03742986 | NYU Langone Health |
Breast Cancer
|
May 2, 2019 | Phase 2 |
| NCT03742102 | AstraZeneca |
Triple Negative Breast Neoplasms
|
December 21, 2018 | Phase 1|Phase 2 |
| NCT01512199 | Daiichi Sankyo, Inc. |
Metastatic Breast Cancer
|
November 2011 | Phase 1|Phase 2 |
| NCT01853748 | Dana-Farber Cancer Institute |
Breast Cancer
|
May 2013 | Phase 2 |
| NCT00077376 | National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
March 2005 | Phase 2 |
| NCT02260531 | Dana-Farber Cancer Institute|Exelixis|Genentech, Inc. |
Breast Cancer|Brain Tumor - Metastatic
|
November 2014 | Phase 2 |
| NCT02402712 | Hoffmann-La Roche |
Breast Cancer
|
May 6, 2015 | Phase 3 |
| NCT02568839 | Thomas Hatschek|Karolinska University Hospital |
Early-Stage Breast Carcinoma|HER-2 Positive Breast Cancer
|
November 2014 | Phase 2|Phase 3 |
| NCT01479179 | M.D. Anderson Cancer Center|Amgen |
Breast Cancer
|
November 2012 | Phase 1|Phase 2 |
| NCT01142778 | Hoffmann-La Roche |
Breast Cancer
|
May 19, 2010 | Phase 2 |
| NCT05594082 | Fudan University |
Breast Cancer
|
November 1, 2021 | |
| NCT02731313 | Hoffmann-La Roche |
Gastric Cancer, Gastroesophageal Junction Cancer
|
July 2012 | |
| NCT03820141 | The Methodist Hospital Research Institute|AstraZeneca |
Breast Cancer
|
March 3, 2020 | Phase 2 |
| NCT03523572 | Daiichi Sankyo, Inc.|Bristol-Myers Squibb|AstraZeneca |
Breast Cancer|Urothelial Carcinoma
|
June 20, 2018 | Phase 1 |
| NCT01351350 | Millennium Pharmaceuticals, Inc.|Takeda |
Advanced Solid Malignancies|Hematologic Malignancies
|
February 28, 2011 | Phase 1 |
| NCT04425018 | Dana-Farber Cancer Institute|MacroGenics|Translational Breast Cancer Research Consortium |
Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|HER2-positive Breast Cancer
|
July 13, 2020 | Phase 2 |
| NCT01170143 | Fudan University|Hoffmann-La Roche |
Breast Cancer
|
August 2009 | Phase 2 |
| NCT01835236 | Swiss Group for Clinical Cancer Research |
Metastatic Breast Cancer
|
March 3, 2013 | Phase 2 |
| NCT03498521 | Hoffmann-La Roche|Foundation Medicine, Inc. |
Cancer of Unknown Primary Site
|
July 10, 2018 | Phase 2 |
| NCT01897441 | Albert Einstein College of Medicine|National Cancer Institute (NCI) |
Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
June 2013 | Not Applicable |
| NCT00005842 | National Cancer Institute (NCI) |
Cancer
|
June 2000 | Phase 1 |
| NCT00393783 | Memorial Sloan Kettering Cancer Center |
Breast Cancer
|
May 2006 | Phase 1 |
| NCT04066790 | Shanghai Jiao Tong University School of Medicine|Jiangsu HengRui Medicine Co., Ltd. |
Breast Cancer
|
September 9, 2019 | Phase 2 |
| NCT00365365 | Sanofi |
Breast Cancer
|
August 2006 | Phase 2 |
| NCT04547907 | Henan Cancer Hospital |
Breast Cancer,Her2 Positive
|
September 18, 2020 | Phase 3 |
| NCT05318339 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Carcinoma, Transitional Cell|HER-2 Gene Amplification
|
March 10, 2022 | Phase 2 |
| NCT03094052 | University of California, San Francisco|Puma Biotechnology, Inc. |
HER2-positive Breast Cancer|Breast Adenocarcinoma|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7
|
October 9, 2018 | Phase 2 |
| NCT00875979 | Hoffmann-La Roche|Roche Pharma AG |
Metastatic Breast Cancer
|
May 2009 | Phase 1|Phase 2 |
| NCT00567190 | Genentech, Inc.|Hoffmann-La Roche |
Metastatic Breast Cancer
|
February 12, 2008 | Phase 3 |
| NCT03501979 | University of Alabama at Birmingham|Translational Breast Cancer Research Consortium|Johns Hopkins University|Seagen Inc.|University of Michigan|Georgetown University|University of California, San Francisco|University of Chicago|Indiana University|University of Washington|University of Texas |
Metastatic Breast Cancer|Leptomeningeal Disease
|
February 20, 2019 | Phase 2 |
| NCT00134680 | Duke University|Genentech, Inc.|Novartis Pharmaceuticals |
Metastatic Breast Cancer
|
January 2000 | Phase 2 |
| NCT02725424 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Gastric Cancer
|
August 2015 | Phase 2 |
| NCT01104935 | Comprehensive Support Project for Oncology Research |
Breast Cancer
|
October 28, 2009 | Phase 3 |
| NCT00820872 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
February 2009 | Phase 2 |
| NCT00842998 | Azienda Ospedaliera Ordine Mauriziano di Torino |
Metastatic Breast Cancer
|
February 2009 | Phase 2 |
| NCT01344863 | Hoffmann-La Roche |
Healthy Volunteer
|
April 2011 | Phase 1 |
| NCT00567554 | German Breast Group|AGO Study Group |
Breast Cancer
|
October 2007 | Phase 3 |
| NCT01273610 | City of Hope Medical Center|GlaxoSmithKline|Novartis |
Breast Neoplasms|HER2+Neu Positive|Geriatric Health Services
|
April 20, 2011 | Phase 2 |
| NCT04639219 | AstraZeneca|Daiichi Sankyo Co., Ltd. |
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
|
December 30, 2020 | Phase 2 |
| NCT01419197 | Hoffmann-La Roche |
Breast Cancer
|
September 2011 | Phase 3 |
| NCT04888663 | Yonsei University |
Recurrent+Metastatic Gastric Cancer
|
February 13, 2018 | Phase 1|Phase 2 |
| NCT02436993 | University of California, Irvine |
Breast Carcinoma
|
April 2015 | Phase 2 |
| NCT05385705 | Vall d´Hebron Institute of Oncology|Clinica Universidad de Navarra, Universidad de Navarra|Puerta de Hierro University Hospital|Hospital del Mar|Banc de Sang i Teixits |
Breast Neoplasms
|
May 11, 2022 | Phase 1 |
| NCT04510285 | Memorial Sloan Kettering Cancer Center |
Esophagogastric Tumors|Gastric Cancer|Gastric Tumor|Esophageal Cancer|Esophageal Neoplasms|Esophageal Tumor|GastroEsophageal Cancer|Gastroesophageal Junction Adenocarcinoma|Gastroesophageal Junction Tumor|Gastroesophageal Junction Cancer
|
August 10, 2020 | Phase 2 |
| NCT05372614 | National Cancer Institute (NCI) |
Metastatic Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm
|
June 17, 2022 | Phase 1 |
| NCT00446030 | Sanofi |
Breast Neoplasms
|
March 2007 | Phase 2 |
| NCT03767335 | Menarini Group |
Advanced or Metastatic Breast Cancer
|
July 19, 2018 | Phase 1 |
| NCT05582499 | Fudan University |
Breast Neoplasm|Breast Cancer|Breast Tumors|Triple-Negative Breast Cancer (TNBC)|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer
|
October 2022 | Phase 1|Phase 2 |
| NCT01325207 | Northwestern University |
Breast Cancer
|
August 1, 2011 | Phase 1|Phase 2 |
| NCT00005635 | Genentech, Inc.|National Cancer Institute (NCI) |
Breast Cancer
|
January 2000 | Phase 2 |
| NCT05207722 | Celularity Incorporated |
Metastatic HER2 Positive Gastroesophageal Junction Cancer
|
April 14, 2022 | Phase 1|Phase 2 |
| NCT02836847 | Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital |
Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer
|
July 2016 | Phase 2 |
| NCT04704934 | Daiichi Sankyo, Inc.|AstraZeneca |
Gastric Cancer, Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
|
May 21, 2021 | Phase 3 |
| NCT04997798 | First Affiliated Hospital of Zhejiang University |
Breast Cancer|Estrogen Receptor Positive Tumor|HER2-positive Breast Cancer
|
December 2021 | Phase 2 |
| NCT02492711 | MacroGenics |
HER-2 Positive Breast Cancer|Metastatic Neoplasm
|
August 24, 2015 | Phase 3 |
| NCT00003612 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
April 1999 | Phase 2 |
| NCT01130337 | Hoffmann-La Roche |
Gastric Cancer
|
July 2010 | Phase 2 |
| NCT03846583 | Dana-Farber Cancer Institute|Eli Lilly and Company |
Breast Cancer
|
June 28, 2020 | Phase 1 |
| NCT04262804 | Zai Lab (Shanghai) Co., Ltd.|Zai Lab (Hong Kong), Ltd. |
Breast Cancer Metastatic
|
January 13, 2020 | Phase 2 |
| NCT00193063 | SCRI Development Innovations, LLC|Eli Lilly and Company|Genentech, Inc. |
Breast Cancer
|
July 2001 | Phase 2 |
| NCT01839500 | Hoffmann-La Roche |
Gastric Cancer
|
April 25, 2013 | |
| NCT03735966 | Henan Cancer Hospital |
HER2 Positive Breast Cancer
|
November 20, 2018 | Phase 2 |
| NCT03417544 | Nancy Lin, MD|Genentech, Inc.|Dana-Farber Cancer Institute |
HER2-positive Metastatic Breast Cancer|Central Nervous System Metastases
|
May 21, 2018 | Phase 2 |
| NCT00567879 | Novartis Pharmaceuticals|Novartis |
Breast Cancer
|
April 2008 | Phase 1|Phase 2 |
| NCT03950271 | Henan Cancer Hospital |
Gastric Cancer
|
January 21, 2020 | Phase 2 |
| NCT04784715 | AstraZeneca|Daiichi Sankyo, Inc. |
Breast Cancer; HER2-positive; Metastatic
|
April 26, 2021 | Phase 3 |
| NCT05131893 | National Institute of Oncology, Hungary |
Breast Cancer
|
March 2022 | |
| NCT01572038 | Hoffmann-La Roche |
Breast Neoplasms
|
June 1, 2012 | Phase 3 |
| NCT02131064 | Hoffmann-La Roche |
Breast Neoplasms
|
June 25, 2014 | Phase 3 |
| NCT00999804 | Baylor Breast Care Center|Translational Breast Cancer Research Consortium|GlaxoSmithKline |
Breast Cancer
|
October 2011 | Phase 2 |
| NCT00625898 | NSABP Foundation Inc|Cancer International Research Group (CIRG)|Hoffmann-La Roche|Genentech, Inc. |
Breast Cancer
|
April 2008 | Phase 3 |
| NCT01402401 | Novartis Pharmaceuticals|Novartis |
Advanced Gastric Cancer
|
November 2011 | Phase 2 |
| NCT00490139 | Novartis Pharmaceuticals|North Central Cancer Treatment Group|National Cancer Institute (NCI)|Breast International Group|Canadian Cancer Trials Group|Novartis |
Neoplasms, Breast
|
May 16, 2007 | Phase 3 |
| NCT03521245 | OmicsWay Corp.|Oncobox Ltd., Russia|Vitamed LLC, Russia|Republican Oncological Dispensary of Karelia Republic, Russia |
HER2-positive Breast Cancer
|
October 1, 2017 | |
| NCT00367250 | Medical University of Vienna |
Metastatic Breast Cancer
|
July 2006 | Phase 1 |
| NCT02598427 | Kimberly Blackwell|Duke University |
HER2 Positive Untreated Metastatic Breast Cancer|Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer
|
May 1, 2017 | Phase 1 |
| NCT00016367 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Lung Cancer
|
May 13, 1999 | Phase 2 |
| NCT00429247 | University Hospital of Crete |
Breast Cancer
|
February 2003 | Phase 2 |
| NCT05325632 | H. Lee Moffitt Cancer Center and Research Institute|ImmunoRestoration |
HER2-positive Breast Cancer
|
November 1, 2021 | Phase 2 |
| NCT02614794 | Seagen Inc. |
HER2 Positive Breast Cancer
|
January 28, 2016 | Phase 2 |
| NCT00548184 | Baylor Breast Care Center|GlaxoSmithKline |
Breast Cancer
|
May 2008 | Phase 2 |
| NCT04759248 | SOLTI Breast Cancer Research Group|Roche Pharma AG |
Breast Cancer
|
March 15, 2021 | Phase 2 |
| NCT02213289 | University of Chicago|AbbVie |
Adenocarcinoma
|
January 20, 2015 | Phase 2 |
| NCT04931342 | Hoffmann-La Roche|GOG Foundation|European Network of Gynaecological Oncological Trial Groups (ENGOT) |
Ovarian Cancer
|
October 7, 2021 | Phase 2 |
| NCT01125566 | Boehringer Ingelheim |
Breast Neoplasms
|
June 22, 2010 | Phase 3 |
| NCT03783936 | Autumn McRee, MD|EMD Serono|University of North Carolina, Chapel Hill|Hoosier Cancer Research Network |
Gastric Adenocarcinoma|Esophageal Adenocarcinoma|Metastasis|HER-2 Gene Amplification
|
January 24, 2019 | Phase 2 |
| NCT02379585 | Western Regional Medical Center |
HER2-positive Breast Cancer
|
January 2013 | Phase 1|Phase 2 |
| NCT00475670 | Hoffmann-La Roche |
Breast Cancer
|
October 2005 | Phase 2 |
| NCT01285466 | Novartis Pharmaceuticals|Novartis |
Metastatic or Locally Advanced Solid Tumors
|
January 2011 | Phase 1 |
| NCT05583110 | Spanish Breast Cancer Research Group|Seagen Inc. |
HER2-positive Metastatic Breast Cancer|Locally Advanced HER2 Positive Breast Carcinoma
|
February 1, 2023 | Phase 2 |
| NCT00788931 | Novartis Pharmaceuticals|Novartis |
HER-2 Positive Breast Cancer|Metastatic Breast Cancer
|
December 2008 | Phase 1 |
| NCT04922008 | Fudan University |
Breast Cancer
|
July 1, 2021 | Phase 2 |
| NCT02465060 | National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Ovarian Carcinoma|Pancreatic Carcinoma|Plasma Cell Myeloma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Plasma Cell Myeloma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer
|
August 12, 2015 | Phase 2 |
| NCT03058939 | University of Chicago |
Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III
|
November 2018 | Phase 2 |
| NCT05378464 | H. Lee Moffitt Cancer Center and Research Institute|Vaccinex Inc. |
HER2-positive Breast Cancer
|
May 31, 2022 | Phase 1 |
| NCT01850628 | NSABP Foundation Inc|Breast Cancer Research Foundation|Washington University School of Medicine |
Breast Cancer
|
July 2013 | |
| NCT04337658 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
HER2-positive Breast Cancer
|
July 1, 2020 | Phase 3 |
| NCT01461057 | Hoffmann-La Roche |
Gastric Cancer
|
December 6, 2011 | Phase 2 |
| NCT05218148 | Aiping Zhou|Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
HER2-positive|Locally Advanced Solid Tumor|Immunotherapy|Sintilimab|S-1|Oxaliplatin|Gastric or Gastroesophageal Junction Adenocarcinoma
|
April 1, 2022 | Phase 2 |
| NCT05593094 | Suzhou Zanrong Pharma Limited |
Advanced Solid Tumors|HER2-positive Breast Cancer
|
October 15, 2020 | Phase 1 |
| NCT03894007 | Renske Altena|Karolinska University Hospital |
Early-stage Breast Cancer|HER2-positive Breast Cancer
|
May 23, 2019 | Phase 2 |
| NCT04986579 | Dana-Farber Cancer Institute|Paxman Coolers Limited|AstraZeneca|Eisai Inc.|Daiichi Sankyo, Inc.|Gilead Sciences |
Metastatic Breast Cancer|Chemotherapy-induced Alopecia
|
October 7, 2021 | Phase 2 |
| NCT01185509 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Genentech, Inc. |
Breast Cancer|Metastatic Breast Cancer
|
November 2010 | Phase 2 |
| NCT00005926 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Pancreatic Cancer|Pancreatic Neoplasm
|
June 2000 | Phase 2 |
| NCT01750073 | University of Nebraska|National Cancer Institute (NCI) |
Estrogen Receptor Negative|Estrogen Receptor Positive|HER2+Neu Negative|HER2+Neu Positive|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive|Stage IA Breast Cancer|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma
|
December 2012 | Phase 2 |
| NCT05408845 | NRG Oncology|National Cancer Institute (NCI) |
Metastatic Salivary Gland Carcinoma|Recurrent Salivary Gland Carcinoma|Stage III Major Salivary Gland Cancer AJCC v8|Stage IV Major Salivary Gland Cancer AJCC v8|Unresectable Salivary Gland Carcinoma
|
November 10, 2022 | Phase 2 |
| NCT02675231 | Eli Lilly and Company |
Hormone Receptor Positive Breast Cancer|HER-2 Positive Breast Cancer
|
May 23, 2016 | Phase 2 |
| NCT01772472 | Hoffmann-La Roche|NSABP Foundation Inc|German Breast Group |
Breast Cancer
|
April 3, 2013 | Phase 3 |
| NCT00574587 | Albert Einstein College of Medicine|Merck Sharp & Dohme LLC |
Breast Cancer
|
December 2007 | Phase 1|Phase 2 |
| NCT01367002 | Yale University|Genentech, Inc. |
Endometrial Cancer
|
June 2011 | Phase 2 |
| NCT02132949 | Hoffmann-La Roche |
Breast Cancer
|
July 14, 2014 | Phase 2 |
| NCT00021255 | Sanofi|Cancer International Research Group (CIRG) |
Breast Neoplasms
|
April 2001 | Phase 3 |
| NCT00670982 | Harold J. Burstein, MD, PhD|Brigham and Women´s Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Genentech, Inc.|New Hampshire Oncology-Hematology PA|Lowell General Hospital|Hartford Hospital|Dana-Farber Cancer Institute |
Breast Cancer
|
May 2008 | Phase 2 |
| NCT00478140 | National Cancer Institute (NCI) |
Adenocarcinoma of the Extrahepatic Bile Duct|Adenocarcinoma of the Gallbladder|Malignant Neoplasm|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer
|
May 2007 | Phase 2 |
| NCT00169104 | Dartmouth-Hitchcock Medical Center|Amgen |
Metastatic Breast Cancer
|
July 2002 | Phase 2|Phase 3 |
| NCT01513083 | Hoffmann-La Roche |
Breast Cancer
|
February 2012 | Phase 1 |
| NCT00398567 | Puma Biotechnology, Inc. |
Advanced Breast Cancer
|
April 4, 2007 | Phase 1|Phase 2 |
| NCT02194166 | Hoffmann-La Roche |
Breast Cancer
|
July 18, 2014 | Phase 3 |
| NCT00126607 | National Cancer Institute (NCI) |
High-grade Salivary Gland Mucoepidermoid Carcinoma|Recurrent Salivary Gland Cancer|Salivary Gland Acinic Cell Tumor|Salivary Gland Adenocarcinoma|Salivary Gland Poorly Differentiated Carcinoma|Stage IVA Salivary Gland Cancer|Stage IVB Salivary Gland Cancer|Stage IVC Salivary Gland Cancer
|
July 2005 | Phase 2 |
| NCT04266249 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8
|
February 11, 2020 | Phase 2 |
| NCT01779050 | Washington University School of Medicine|Genentech, Inc. |
Breast Neoplasms
|
December 19, 2013 | Phase 2 |
| NCT01702558 | Hoffmann-La Roche |
Breast Cancer|Gastric Cancer
|
December 3, 2012 | Phase 2 |
| NCT00372424 | Pfizer |
Breast Cancer
|
December 2006 | Phase 1 |
| NCT04208178 | Novartis Pharmaceuticals|Novartis |
Advanced HER2&addition;Breast Cancer
|
July 16, 2020 | Phase 3 |
| NCT01265927 | Indiana University|Breast Cancer Research Foundation|Geron Corporation |
Breast Neoplasms
|
January 2011 | Phase 1 |
| NCT02947685 | Alliance Foundation Trials, LLC.|Pfizer|German Breast Group|Fondazione Michelangelo|PrECOG, LLC.|Breast Cancer Trials, Australia and New Zealand|Syneos Health|SOLTI Breast Cancer Research Group|UNICANCER |
HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer
|
June 21, 2017 | Phase 3 |
| NCT03595592 | Fondazione Michelangelo|Hoffmann-La Roche |
Invasive Breast Cancer
|
September 7, 2018 | Phase 3 |
| NCT01688609 | National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
July 2012 | Phase 2 |
| NCT00033514 | Jonsson Comprehensive Cancer Center|Genentech, Inc. |
Breast Cancer
|
August 2001 | Phase 1|Phase 2 |
| NCT00976989 | Hoffmann-La Roche |
Breast Cancer
|
November 2009 | Phase 2 |
| NCT04158258 | Hoffmann-La Roche|Latin American Cooperative Oncology Group |
Breast Cancer
|
February 21, 2020 | |
| NCT04049409 | Taizhou Mabtech Pharmaceutical Co.,Ltd |
Healthy Volunteers
|
June 17, 2019 | Phase 1 |
| NCT00810017 | Medstar Health Research Institute|Genentech, Inc. |
HER-2 Positive Metastatic Breast Cancer
|
February 2009 | Phase 2 |
| NCT04539938 | Seagen Inc. |
HER2 Positive Breast Cancer
|
December 1, 2020 | Phase 2 |
| NCT03765983 | Dana-Farber Cancer Institute|Kazia Therapeutics Limited |
Breast Cancer
|
February 11, 2019 | Phase 2 |
| NCT00068757 | European Organisation for Research and Treatment of Cancer - EORTC |
Breast Cancer
|
August 2003 | Phase 1 |
| NCT01921335 | Dana-Farber Cancer Institute|Array BioPharma|Breast Cancer Research Foundation |
Brain Metastases From HER2 and Breast Cancer|Advanced HER2-positive Breast Cancer
|
August 2013 | Phase 1 |
| NCT02100917 | Meiji Seika Pharma Co., Ltd.|Dong-A Pharmaceutical |
Healthy Volunteer
|
January 2014 | Phase 1 |
| NCT04420598 | MedSIR|Daiichi Sankyo, Inc. |
Advanced Breast Cancer|HER2-positive Breast Cancer|Brain Metastases|Leptomeningeal Metastasis
|
May 25, 2020 | Phase 2 |
| NCT00542451 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Genentech, Inc. |
Breast Cancer|Carcinoma of the Breast
|
October 2007 | Phase 2 |
| NCT03013504 | Prestige Biopharma Limited |
HER2 Positive Breast Cancer
|
January 1, 2018 | Phase 3 |
| NCT01276041 | Memorial Sloan Kettering Cancer Center|Genentech, Inc.|University of Pennsylvania |
Breast Cancer
|
January 5, 2011 | Phase 2 |
| NCT00004856 | National Cancer Institute (NCI) |
Distal Urethral Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Proximal Urethral Cancer|Recurrent Bladder Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder|Urethral Cancer Associated With Invasive Bladder Cancer
|
July 2002 | Phase 2 |
| NCT00429104 | M.D. Anderson Cancer Center|Bayer |
Breast Cancer
|
August 2002 | Phase 2 |
| NCT04383275 | Fudan University |
Breast Cancer
|
May 15, 2020 | Phase 2 |
| NCT02003209 | National Cancer Institute (NCI)|NRG Oncology |
HER2-Positive Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7
|
January 15, 2014 | Phase 3 |
| NCT03185988 | Shen Lin|Peking University |
Targeted Therapy|HER2|Biliary Tract Cancer|Esophageal Squamous Cell Carcinoma|Colorectal Cancer
|
July 1, 2017 | Phase 2 |
| NCT00171847 | Novartis Pharmaceuticals|Roche - Prof. Dr. Jens Huober et al.|Novartis |
Metastatic Breast Cancer
|
March 2003 | Phase 4 |
| NCT01548677 | European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche|Janssen Diagnostics, LLC|SUCCESS|UNICANCER |
Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Circulating Tumor Cells
|
April 2013 | Phase 2 |
| NCT01004172 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Genentech, Inc. |
Metastatic Breast Cancer|Breast Cancer|Progressive Breast Cancer
|
November 2009 | Phase 2 |
| NCT02059876 | Guangdong Provincial People´s Hospital |
Breast Cancer
|
November 2013 | Phase 2 |
| NCT04639271 | Shandong Cancer Hospital and Institute |
Breast Cancer|HER2-positive Breast Cancer
|
January 1, 2021 | Phase 2 |
| NCT00427427 | Jonsson Comprehensive Cancer Center |
Breast Cancer
|
January 2007 | Phase 2 |
| NCT05415215 | Hoffmann-La Roche |
Early Breast Cancer|Locally Advanced Breast Cancer|Inflammatory Breast Cancer
|
July 5, 2022 | Phase 3 |
| NCT04102618 | Oncolytics Biotech|SOLTI Breast Cancer Research Group |
Breast Cancer
|
March 29, 2019 | Early Phase 1 |
| NCT01301729 | Hoffmann-La Roche |
Breast Cancer
|
March 2011 | Phase 4 |
| NCT02339532 | UNICANCER |
Breast Cancer
|
January 2015 | Phase 2 |
| NCT00464646 | NSABP Foundation Inc|Genentech, Inc.|International Drug Development Institute |
Breast Cancer
|
May 2007 | Phase 2 |
| NCT00824733 | Bhuvaneswari Ramaswamy|Pfizer|Ohio State University Comprehensive Cancer Center |
Breast Cancer
|
February 2009 | Phase 2 |
| NCT02472964 | Mylan Inc.|Mylan GmbH|Viatris Inc. |
Breast Cancer
|
July 2012 | Phase 3 |
| NCT02345772 | Western Regional Medical Center |
HER2-positive Breast Cancer|ER-positive Breast Cancer
|
July 2014 | Phase 1|Phase 2 |
| NCT04220203 | Seagen Inc.|Parexel |
HER2-positive Breast Cancer
|
||
| NCT00593697 | Finnish Breast Cancer Group |
Breast Neoplasms
|
January 2008 | Phase 3 |
| NCT03615326 | Merck Sharp & Dohme LLC |
Gastric Neoplasms|Gastroesophageal Junction Adenocarcinoma
|
October 5, 2018 | Phase 3 |
| NCT04150640 | University of Wisconsin, Madison|Ipsen |
Esophageal Adenocarcinoma|Gastric Adenocarcinoma
|
July 13, 2020 | Phase 2 |
| NCT02827877 | City of Hope Medical Center|National Cancer Institute (NCI) |
HER2 Positive Breast Carcinoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
|
July 15, 2016 | Phase 2 |
| NCT02250209 | Chinese PLA General Hospital |
Gastric Cancer
|
July 2014 | Phase 2 |
| NCT05180006 | Gustave Roussy, Cancer Campus, Grand Paris|Hoffmann-La Roche |
Breast Cancer
|
February 24, 2022 | Phase 2 |
| NCT05311189 | Shanghai Zhongshan Hospital |
HER2-positive Gastric Cancer
|
April 15, 2022 | Phase 2 |
| NCT00199212 | Jules Bordet Institute |
Carcinoma Breast Stage IV
|
October 2003 | Phase 1 |
| NCT00811135 | Hoffmann-La Roche |
Breast Cancer
|
December 2008 | Phase 2 |
| NCT01428414 | Zhimin Shao|Roche Pharma AG|Fudan University |
HER-2 Positive Breast Cancer
|
August 2011 | Phase 2 |
| NCT04644237 | Daiichi Sankyo, Inc.|AstraZeneca |
Non-Small Cell Lung Cancer
|
March 19, 2021 | Phase 2 |
| NCT04042051 | Cancer Trials Ireland |
HER2-positive Breast Cancer|Metastatic Breast Cancer|Locally Advanced Breast Cancer|Unresectable Breast Cancer
|
November 12, 2019 | Phase 1 |
| NCT05429684 | First Affiliated Hospital Xi´an Jiaotong University |
HER2&addition; Breast Cancer
|
January 1, 2021 | Phase 3 |
| NCT00387907 | Sanofi |
Advanced Breast Cancer|Breast Cancer|Metastatic Breast Cancer
|
October 2006 | Phase 2 |
| NCT03101748 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Breast Inflammatory Carcinoma|Locally Advanced Breast Carcinoma|Metastatic Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7
|
January 29, 2018 | Phase 1|Phase 2 |
| NCT03144947 | Gruppo Oncologico Italiano di Ricerca Clinica|University Hospital of Parma: Department of Biomedical, Biotechnological and Translational Sciences, Pathological Anatomy and Histology Unit|University Hospital of Parma:Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology|University Hospital of Parma:Statistica medica ed epidemiologia clinica-UO Ricerca e Innovazione|Clirest s.r.l.|Mipharm SpA|Arithmos srl|Temas srl |
Cancer, Breast
|
November 29, 2016 | Phase 2 |
| NCT03947242 | Henan Cancer Hospital |
HER2 Positive Breast Cancer
|
June 1, 2019 | Not Applicable |
| NCT04589845 | Hoffmann-La Roche |
Solid Tumors
|
January 18, 2021 | Phase 2 |
| NCT01048099 | SCRI Development Innovations, LLC|Prometheus Laboratories|Genentech, Inc. |
Breast Cancer
|
January 2011 | Not Applicable |
| NCT01847001 | Columbia University |
Locally Advanced Malignant Neoplasm|Breast Cancer
|
October 2012 | Phase 2 |
| NCT01613482 | Centre Oscar Lambret |
Breast Cancer|Metastasis|Sur-expressing Her2-neu
|
October 2007 | Phase 3 |
| NCT02581748 | Shanghai Henlius Biotech |
Healthy
|
September 16, 2015 | Phase 1 |
| NCT03523585 | Daiichi Sankyo, Inc.|Daiichi Sankyo Co., Ltd.|AstraZeneca |
Breast Cancer
|
August 1, 2018 | Phase 3 |
| NCT01007942 | Novartis Pharmaceuticals|Novartis |
HER2+Neu Over-expressing Locally Advanced Breast Cancer|Metastatic Breast Cancer
|
October 2009 | Phase 3 |
| NCT01042379 | QuantumLeap Healthcare Collaborative |
Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer
|
March 1, 2010 | Phase 2 |
| NCT04014075 | Daiichi Sankyo, Inc.|AstraZeneca |
Adenocarcinoma Gastric Stage IV With Metastases|Adenocarcinoma - GEJ
|
November 26, 2019 | Phase 2 |
| NCT03304080 | Icahn School of Medicine at Mount Sinai|Herbert Irving Comprehensive Cancer Center|Weill Medical College of Cornell University|NYU Langone Health |
Breast Neoplasms|Breast Diseases
|
December 20, 2017 | Phase 1|Phase 2 |
| NCT00019812 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Breast Cancer
|
August 1999 | Phase 2 |
| NCT02925234 | The Netherlands Cancer Institute|Amgen|AstraZeneca|Bayer|Bristol-Myers Squibb|Novartis|Roche Pharma AG|Merck Sharp & Dohme LLC|Boehringer Ingelheim|Ipsen|Eisai Inc.|Pfizer|Clovis Oncology, Inc.|Eli Lilly and Company|Janssen, LP |
Cancer|Tumors|Neoplasm|Neoplasia
|
August 2016 | Phase 2 |
| NCT04752059 | Medical University of Vienna|Daiichi Sankyo, Inc. |
Breast Cancer Stage IV
|
July 28, 2020 | Phase 2 |
| NCT01810393 | Hoffmann-La Roche |
Breast Cancer
|
June 11, 2013 | Phase 3 |
| NCT03013881 | United BioPharma|Tri-Service General Hospital |
Breast Neoplasm
|
March 5, 2018 | Phase 1 |
| NCT03014076 | Cancer Insight, LLC |
Breastcancer
|
January 2008 | Phase 1 |
| NCT02390427 | Otto Metzger|Genentech, Inc.|Dana-Farber Cancer Institute |
Metastatic Breast Cancer|Recurrent Breast Cancer
|
April 20, 2015 | Phase 1 |
| NCT03238495 | Qamar Khan|University of Kansas Medical Center |
HER2-positive Breast Cancer
|
August 15, 2017 | Phase 2 |
| NCT00811993 | Hoffmann-La Roche |
Neoplasms
|
February 2009 | Phase 1 |
| NCT01204372 | Institut du Cancer de Montpellier - Val d´Aurelle |
Metastatic Pancreatic Adenocarcinoma
|
June 2010 | Phase 2 |
| NCT00022672 | Hoffmann-La Roche|Genentech, Inc. |
Breast Cancer
|
January 2001 | Phase 3 |
| NCT01373710 | Institut Curie|Hoffmann-La Roche|Centre Leon Berard|Groupe Hospitalier Pitie-Salpetriere|Centre Oscar Lambret|Centre Francois Baclesse|Institut Bergonié|University Hospital, Toulouse|Institut du Cancer de Montpellier - Val d´Aurelle|University Hospital, Grenoble |
Metastatic Breast Cancer|Carcinomatous Meningitis
|
May 19, 2011 | Phase 1|Phase 2 |
| NCT01503905 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Breast Cancer Nos Premenopausal
|
December 2011 | Not Applicable |
| NCT00915018 | Puma Biotechnology, Inc. |
Breast Cancer
|
August 21, 2009 | Phase 2 |
| NCT01901146 | Amgen|Actavis Inc. |
Breast Cancer
|
April 29, 2013 | Phase 3 |
| NCT01816594 | Novartis Pharmaceuticals|Breast International Group|German Breast Group|SOLTI Breast Cancer Research Group|Novartis |
HER2-positive Newly Diagnosed, Primary Breast Cancer
|
September 3, 2013 | Phase 2 |
| NCT00928330 | Genentech, Inc. |
Metastatic Breast Cancer
|
July 2009 | Phase 1 |
| NCT04740918 | Hoffmann-La Roche |
Metastatic Breast Cancer
|
June 7, 2021 | Phase 3 |
| NCT00428922 | Bhuvaneswari Ramaswamy|Genentech, Inc.|Case Comprehensive Cancer Center|University of Pittsburgh|Ohio State University Comprehensive Cancer Center |
Breast Cancer
|
June 14, 2007 | Phase 2 |
| NCT01641939 | Hoffmann-La Roche |
Gastric Cancer
|
September 3, 2012 | Phase 2|Phase 3 |
| NCT02725541 | Jenny C. Chang, MD|Genentech, Inc.|The Methodist Hospital Research Institute |
Breast Cancer
|
March 2016 | Phase 2 |
| NCT02656589 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Sun Yat-sen University|Huiping Li,M.D., Ph.D.,Peking University Cancer Hospital |
Breast Cancer
|
June 2015 | |
| NCT04341181 | Ulrik Lassen|Roche Pharma AG|Pfizer|GlaxoSmithKline|Rigshospitalet, Denmark |
Cancer|Tumors|Neoplasms|Neoplasia
|
August 24, 2020 | Phase 2 |
| NCT04481932 | Peking University |
HER2-positive Breast Cancer
|
July 2020 | Phase 2 |
| NCT00054587 | UNICANCER |
Breast Cancer
|
June 2001 | Phase 3 |
| NCT05253651 | Seagen Inc.|Merck Sharp & Dohme LLC |
Colorectal Neoplasms
|
November 30, 2022 | Phase 3 |
| NCT04789096 | Breast Cancer Trials, Australia and New Zealand |
Breast Cancer|HER2-positive Breast Cancer
|
December 2022 | Phase 2 |
| NCT05356897 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Metastatic Colon Adenocarcinoma|Metastatic Colorectal Adenocarcinoma|Metastatic Rectal Adenocarcinoma|Stage IV Colon Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Rectal Cancer AJCC v8
|
November 30, 2022 | Phase 2 |
| NCT00023998 | National Cancer Institute (NCI) |
Metastatic Osteosarcoma
|
July 2001 | Phase 2 |
| NCT01922921 | University of Washington|National Cancer Institute (NCI)|Office of Cancer Complementary and Alternative Medicine |
HER2+Neu Positive|Recurrent Breast Carcinoma|Stage IV Breast Cancer
|
February 5, 2014 | Phase 1|Phase 2 |
| NCT01290718 | Hoffmann-La Roche |
Breast Cancer
|
December 2011 | Phase 2 |
| NCT04675827 | Jules Bordet Institute|Breast International Group|Hoffmann-La Roche|International Drug Development Institute|Institut Curie |
HER2-positive Breast Cancer|ER-Negative Breast Cancer|PR-Negative Breast Cancer|Node-negative Breast Cancer
|
January 17, 2022 | Phase 2 |
| NCT00458237 | Beth Israel Deaconess Medical Center|Novartis Pharmaceuticals|Dana-Farber Cancer Institute |
Breast Cancer
|
April 2007 | Phase 1|Phase 2 |
| NCT00053339 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Stage IV Breast Cancer|Recurrent Breast Cancer
|
Phase 3 | |
| NCT01953926 | Puma Biotechnology, Inc. |
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
|
September 30, 2013 | Phase 2 |
| NCT01774851 | Merrimack Pharmaceuticals |
HER-2 Gene Amplification|Esophagus Cancer|Gastroesophageal Junction Cancer|Stomach Cancer
|
January 2013 | Phase 2 |
| NCT03365882 | Southwest Oncology Group|National Cancer Institute (NCI) |
Colon Adenocarcinoma|ERBB2 Gene Amplification|Rectal Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage III Colon Cancer AJCC v7|Stage III Rectal Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7|Stage IV Colon Cancer AJCC v7|Stage IV Rectal Cancer AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7
|
October 9, 2017 | Phase 2 |
| NCT00364611 | Sanofi |
Breast Cancer
|
August 2006 | Phase 2 |
| NCT01985893 | Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.|OnkoDataMed GmbH |
Metastatic Breast Cancer
|
September 2013 | Phase 2 |
| NCT05132582 | Seagen Inc.|Merck Sharp & Dohme LLC |
HER2 Positive Breast Cancer
|
March 7, 2022 | Phase 3 |
| NCT01423695 | WiSP Wissenschaftlicher Service Pharma GmbH|Bristol-Myers Squibb|Roche Pharma AG |
Metastatic Breast Cancer
|
February 2001 | Phase 2 |
| NCT00788333 | Bristol-Myers Squibb |
Breast Cancer
|
July 2009 | Phase 1|Phase 2 |
| NCT03329378 | Icahn School of Medicine at Mount Sinai |
Locally Advanced Breast Cancer
|
January 30, 2019 | Phase 2 |
| NCT01971515 | EMD Serono |
Solid Tumor
|
December 13, 2013 | Phase 1 |
| NCT00004925 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
August 1999 | Phase 1|Phase 2 |
| NCT00337649 | Hoffmann-La Roche |
Breast Cancer
|
May 2004 | Phase 2 |
| NCT03556358 | Tanvex BioPharma USA, Inc. |
Breast Cancer|Breast Neoplasms|HER2-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
June 28, 2018 | Phase 3 |
| NCT00943410 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
March 2000 | Phase 2 |
| NCT00042809 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
May 2002 | Phase 1 |
| NCT01304784 | Merrimack Pharmaceuticals |
HER-2 Gene Amplification
|
January 2011 | Phase 1 |
| NCT01503983 | Fundación para el Progreso de la Oncología en Cantabria |
Stage IV Gastric Cancer With Metastasis
|
August 2011 | Phase 2 |
| NCT01137994 | GlaxoSmithKline |
Neoplasms, Breast
|
October 2011 | Phase 2 |
| NCT00127933 | Hoffmann-La Roche |
Breast Cancer
|
August 2005 | Phase 4 |
| NCT01880385 | Association Tunisienne de lutte Contre le Cancer|Hoffmann-La Roche|Sanofi |
Inflammatory Breast Cancer
|
March 2011 | Phase 1 |
| NCT03006172 | Genentech, Inc. |
Breast Cancer|Solid Tumor
|
December 13, 2016 | Phase 1 |
| NCT00444587 | Hoffmann-La Roche |
Breast Cancer
|
March 2007 | Phase 2 |
| NCT01565083 | Hoffmann-La Roche |
Breast Cancer
|
April 2012 | Phase 2 |
| NCT00301899 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Breast Cancer
|
December 2005 | Phase 2 |
| NCT00386685 | Sanofi |
Breast Neoplasms
|
July 2006 | Phase 2 |
| NCT00768859 | The Netherlands Cancer Institute |
Breast Cancer|HER2 Positive
|
September 2008 | Phase 2 |
| NCT04172259 | Sun Yat-sen University|First Affiliated Hospital, Sun Yat-Sen University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Breast Cancer|Neoadjuvant Chemotherapy
|
January 10, 2019 | Phase 2 |
| NCT03264547 | Japan Breast Cancer Research Group|Eisai Co., Ltd. |
Breast Cancer
|
August 28, 2017 | Phase 3 |
| NCT00470704 | Nancy Lin, MD|GlaxoSmithKline|Novartis|Dana-Farber Cancer Institute |
Breast Cancer
|
May 14, 2007 | Phase 2 |
| NCT01670877 | Washington University School of Medicine|Puma Biotechnology, Inc.|United States Department of Defense |
Breast Neoplasms
|
December 11, 2012 | Phase 2 |
| NCT02896855 | Hoffmann-La Roche |
Breast Cancer
|
September 13, 2016 | Phase 3 |
| NCT04419181 | University of Rochester |
HER2-positive Breast Cancer
|
June 1, 2023 | Phase 2 |
| NCT00251433 | Novartis Pharmaceuticals|Novartis |
Neoplasms, Breast
|
September 26, 2005 | Phase 1 |
| NCT04329065 | University of Washington|United States Department of Defense |
Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8
|
April 20, 2022 | Phase 2 |
| NCT02649686 | Canadian Cancer Trials Group|AstraZeneca |
Metastatic Breast Cancer
|
April 21, 2016 | Phase 1 |
| NCT01254136 | Incyte Corporation |
Breast Cancer
|
October 2010 | Phase 1|Phase 2 |
| NCT04551521 | German Cancer Research Center |
Metastatic or Locally Advanced Malignancies
|
October 12, 2021 | Phase 2 |
| NCT00022529 | National Cancer Institute (NCI) |
Unspecified Adult Solid Tumor, Protocol Specific
|
July 2001 | Phase 1 |
| NCT05048797 | AstraZeneca|Daiichi Sankyo, Inc. |
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
October 28, 2021 | Phase 3 |
| NCT03412643 | NSABP Foundation Inc|Celcuity, LLC|Genentech, Inc. |
HER2-negative Breast Cancer
|
May 14, 2018 | Phase 2 |
| NCT02594761 | Mylan Pharmaceuticals Inc|Mylan GmbH|MylanPharma |
Healthy
|
August 2013 | Phase 1 |
| NCT00317720 | M.D. Anderson Cancer Center|Novartis |
Breast Cancer|Neoplasm Metastasis
|
April 2006 | Phase 1|Phase 2 |
| NCT00303108 | US Oncology Research|Ortho Biotech, Inc.|Tibotec Pharmaceutical Limited |
Metastatic Breast Cancer
|
December 2005 | Phase 2 |
| NCT00490646 | R-Pharm |
Metastatic Breast Cancer
|
February 2008 | Phase 2 |
| NCT01855828 | Yale University|Genentech, Inc. |
Her2-Positive Breast Cancer
|
September 2013 | Phase 2 |
| NCT03907800 | Ruijin Hospital |
Breast Cancer|Triple Negative Breast Cancer|HER2-positive Breast Cancer
|
April 1, 2019 | Phase 2 |
| NCT04973319 | Shengjing Hospital |
Breast Cancer
|
August 1, 2021 | Phase 3 |
| NCT01434303 | National Cancer Institute (NCI) |
HER2+Neu Positive|Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7
|
January 10, 2012 | Phase 1 |
| NCT01557764 | Washington University School of Medicine |
Breast Neoplasms
|
September 2012 | Phase 2 |
| NCT03613168 | Changhoon Yoo|Asan Medical Center |
Cholangiocarcinoma|Biliary Tract Cancer|HER-2 Protein Overexpression|HER-2 Gene Amplification
|
June 1, 2019 | Phase 2 |
| NCT02019277 | Hoffmann-La Roche |
Breast Cancer
|
December 5, 2013 | Phase 3 |
| NCT04873362 | Hoffmann-La Roche |
Breast Cancer
|
May 4, 2021 | Phase 3 |
| NCT02658461 | Hoffmann-La Roche |
Breast Cancer
|
February 2012 | |
| NCT01875367 | Spanish Breast Cancer Research Group |
Breast Cancer
|
September 18, 2013 | Phase 3 |
| NCT00755313 | University of California, San Francisco|National Cancer Institute (NCI) |
Breast Cancer|Chemotherapeutic Agent Toxicity|Cognitive+Functional Effects|Fatigue|Long-term Effects Secondary to Cancer Therapy in Adults|Neurotoxicity|Psychosocial Effects of Cancer and Its Treatment
|
May 2007 | |
| NCT03084939 | Hoffmann-La Roche |
Breast Cancer
|
April 24, 2017 | Phase 3 |
| NCT00003539 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
April 1998 | Phase 2 |
| NCT05041842 | UNICANCER|Seagen Inc.|ARCAGY+ GINECO GROUP |
Metastatic Breast Cancer With a Isolated Brain Progression
|
December 17, 2021 | Phase 2 |
| NCT03425656 | AryoGen Pharmed Co. |
Malignant Neoplasm of Breast
|
July 9, 2016 | Phase 3 |
| NCT03432741 | Mayo Clinic|National Cancer Institute (NCI) |
Breast Adenocarcinoma|Metastatic Breast Carcinoma|Recurrent Breast Carcinoma|Recurrent Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Breast Carcinoma|Refractory Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Nodal Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Breast Cancer AJCC v6 and v7
|
March 27, 2018 | Phase 1 |
| NCT00148668 | Eric Winer, MD|Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Yale University |
Breast Cancer
|
December 2003 | Phase 2 |
| NCT00379015 | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan |
Breast Cancer
|
January 2006 | Phase 2 |
| NCT01570036 | George E. Peoples|Genentech, Inc.|Sellas Life Sciences Group|Cancer Insight, LLC |
Breast Cancer
|
May 21, 2013 | Phase 2 |
| NCT01160211 | Novartis Pharmaceuticals|GlaxoSmithKline|Novartis |
Neoplasms, Breast
|
May 5, 2011 | Phase 3 |
| NCT00524303 | GlaxoSmithKline |
Neoplasms, Breast
|
August 2007 | Phase 2 |
| NCT04908813 | Shanghai Henlius Biotech |
Gastric Cancer
|
September 29, 2021 | Phase 2 |
| NCT01827163 | Memorial Sloan Kettering Cancer Center|GlaxoSmithKline |
HER2-Positive Early Stage Breast Cancer
|
April 2013 | Phase 2 |
| NCT04290793 | Hebei Medical University Fourth Hospital |
Breast Cancer
|
March 1, 2020 | Phase 2|Phase 3 |
| NCT00256243 | Rita Sanghvi, Mehta|University of California, Irvine |
Breast Cancer
|
April 2004 | Phase 2 |
| NCT00440622 | Hellenic Oncology Research Group|University Hospital of Crete |
Breast Cancer
|
April 2003 | Phase 3 |
| NCT00509769 | Genentech, Inc. |
Metastatic Breast Cancer
|
July 2007 | Phase 2 |
| NCT05076695 | Fudan University |
Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer
|
October 15, 2021 | Phase 2 |
| NCT00847366 | AEterna Zentaris |
Non Small Cell Lung Cancer|Solid Tumors|Metastatic Breast Cancer|Sarcomas
|
May 2008 | Not Applicable |
| NCT04464967 | NKGen Biotech, Inc. |
Advanced Solid Tumor|Metastatic Cancer|HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER-2 Protein Overexpression|Esophageal Cancer|Ovarian Cancer|Endometrium Cancer|Bladder Cancer|Pancreatic Cancer|Colorectal Cancer|Non Small Cell Lung Cancer|EGF-R Positive Non-Small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma|Triple Negative Breast Cancer|Cervical Cancer|Sarcoma
|
March 2021 | Phase 1|Phase 2 |
| NCT00009997 | NYU Langone Health|National Cancer Institute (NCI) |
Breast Cancer
|
March 1999 | Phase 1 |
| NCT02448420 | SOLTI Breast Cancer Research Group |
Metastatic Breast Cancer
|
July 2015 | Phase 2 |
| NCT00028535 | National Cancer Institute (NCI) |
Male Breast Cancer|Recurrent Breast Cancer|Recurrent Endometrial Carcinoma|Recurrent Gastric Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Small Cell Lung Cancer
|
November 2001 | Phase 1 |
| NCT04197687 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Breast Adenocarcinoma|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7
|
February 20, 2020 | Phase 2 |
| NCT02289833 | Hoffmann-La Roche |
Non-Small Cell Lung Cancer
|
December 15, 2014 | Phase 2 |
| NCT00826267 | Boehringer Ingelheim |
Breast Neoplasms
|
January 2009 | Phase 2 |
| NCT01745965 | West German Study Group|Roche Pharma AG |
Breast Cancer
|
November 2012 | Phase 2 |
| NCT02344472 | Prof. W. Janni|Roche Pharma AG|Novartis Pharmaceuticals|Eisai GmbH|Celgene Corporation|University of Ulm |
Metastatic Breast Cancer
|
September 2015 | Phase 3 |
| NCT04109391 | Tanvex BioPharma USA, Inc. |
HER2-positive Breast Cancer|Early-stage Breast Cancer|Breast Cancer|Breast Neoplasms|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
August 20, 2019 | Phase 3 |
| NCT04294628 | National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|HER2-Positive Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm
|
July 14, 2020 | Phase 1 |
| NCT00107393 | Tohoku University|National Cancer Institute (NCI) |
Breast Cancer
|
June 2003 | Phase 2 |
| NCT00433095 | Ludwig-Maximilians - University of Munich|Pierre Fabre Laboratories |
Carcinoma Breast Stage IV
|
Phase 2 | |
| NCT00615602 | Hellenic Oncology Research Group|University Hospital of Crete |
Breast Cancer
|
October 2004 | Phase 3 |
| NCT01966471 | Hoffmann-La Roche |
Breast Cancer
|
January 31, 2014 | Phase 3 |
| NCT00006123 | Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute |
Breast Cancer
|
July 2000 | Phase 1|Phase 2 |
| NCT04175171 | Genor Biopharma Co., Ltd. |
Metastatic Breast Cancer
|
November 7, 2011 | Phase 1 |
| NCT04957212 | Cinnagen |
HER2-positive Breast Cancer
|
August 11, 2018 | Phase 3 |
| NCT03433313 | EirGenix, Inc. |
Breast Cancer
|
October 16, 2018 | Phase 3 |
| NCT04215159 | Jin-Hee Ahn|Asan Medical Center |
HER-2 Protein Overexpression|HER-2 Gene Amplification
|
December 30, 2019 | Phase 2 |
| NCT05458674 | Criterium, Inc. |
Breast Cancer
|
November 15, 2022 | Phase 2 |
| NCT00006228 | National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
July 2000 | Phase 2 |
| NCT04629846 | Qilu Pharmaceutical Co., Ltd. |
Breast Cancer
|
November 2020 | Phase 3 |
| NCT00148681 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital |
Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer
|
May 2001 | Phase 2 |
| NCT00667251 | Novartis Pharmaceuticals|NCIC Clinical Trials Group|Novartis |
Breast Cancer
|
October 7, 2008 | Phase 3 |
| NCT00331552 | University of Washington|National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
February 2006 | Phase 1|Phase 2 |
| NCT00533936 | Instituto Nacional de Cancerologia, Columbia|National Cancer Institute (NCI) |
Breast Cancer
|
September 2006 | Phase 2 |
| NCT01077648 | GlaxoSmithKline |
Cancer
|
February 2010 | |
| NCT04928261 | Ottawa Hospital Research Institute |
Breast Cancer
|
December 13, 2021 | Phase 4 |
| NCT05301010 | Nanogen Pharmaceutical Biotechnology Joint Stock Company|Vietstar Biomedical Research|MedProve Inc |
Breast Cancer Metastatic|Breast Cancer Recurrent|Breast Cancer Female
|
February 2, 2018 | Phase 3 |
| NCT00968682 | Cancer Trials Ireland |
Breast Cancer|Cardiac Toxicity
|
April 2008 | |
| NCT03242239 | Alteogen, Inc.|Cristália Produtos Químicos Farmacêuticos Ltda. |
Healthy
|
February 9, 2016 | Phase 1 |
| NCT01388647 | Vector Oncology|Eisai Inc. |
HER-2 Positive Breast Cancer
|
August 2011 | Phase 1|Phase 2 |
| NCT04858516 | Guangdong Provincial People´s Hospital |
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
|
April 30, 2021 | Phase 2 |
| NCT02999672 | Hoffmann-La Roche |
Bladder Cancer|Pancreas Cancer|Cholangiocellular Carcinoma
|
December 23, 2016 | Phase 2 |
| NCT04585958 | National Cancer Institute (NCI) |
Endometrial Serous Adenocarcinoma|Metastatic Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm
|
January 4, 2021 | Phase 1 |
| NCT03418558 | Fondazione del Piemonte per l´Oncologia |
Metastatic Colorectal Cancer
|
July 8, 2015 | Phase 2 |
| NCT01828736 | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG |
Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder
|
February 9, 2004 | Phase 2 |
| NCT04989816 | AstraZeneca|Daiichi Sankyo Co., Ltd. |
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
|
August 20, 2021 | Phase 2 |
| NCT00250874 | Zeneus Pharma |
Metastatic Breast Cancer
|
December 2003 | Phase 2 |
| NCT00968968 | Novartis Pharmaceuticals|Novartis |
Cancer
|
January 20, 2010 | Phase 3 |
| NCT02774421 | University of Colorado, Denver|Children´s Hospital Colorado |
Posterior Fossa Ependymoma (PFEPN)
|
December 2016 | Phase 1 |
| NCT02013765 | Hoffmann-La Roche |
Urinary Tract Cancer
|
January 2001 | Phase 2 |
| NCT00769470 | Translational Oncology Research International|National Cancer Institute (NCI)|University of California, Los Angeles |
Breast Cancer
|
April 2009 | Phase 2 |
| NCT00006825 | NYU Langone Health|National Cancer Institute (NCI) |
Breast Cancer
|
July 2000 | Phase 1|Phase 2 |
| NCT03716180 | Dana-Farber Cancer Institute|Susan G. Komen Breast Cancer Foundation|Breast Cancer Research Foundation|Terri Brodeur Breast Cancer Foundation |
Breast Cancer
|
November 5, 2018 | Phase 1 |
| NCT02682693 | German Breast Group|Amgen|Celgene Corporation |
Breast Cancer Female NOS|Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer|Tubular Breast Cancer Stage III
|
February 13, 2017 | Phase 2 |
| NCT01649271 | Boehringer Ingelheim |
Breast Neoplasms|Stomach Neoplasms
|
July 23, 2012 | Phase 1 |
| NCT00288002 | German Breast Group|National Cancer Institute (NCI) |
Breast Cancer
|
January 2005 | Phase 3 |
| NCT01597414 | European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche |
Elderly Metastatic Breast Cancer Population
|
June 2013 | Phase 2 |
| NCT00434031 | National Cancer Institute, Naples |
Breast Cancer
|
September 2007 | Phase 2 |
| NCT01950182 | Sun Yat-sen University |
Breast Cancer
|
September 16, 2013 | Phase 3 |
| NCT01454804 | M.D. Anderson Cancer Center |
Advanced Cancers
|
October 2011 | Phase 1 |
| NCT01796197 | Dana-Farber Cancer Institute |
Breast Cancer
|
August 2013 | Phase 2 |
| NCT02062983 | National Guard Health Affairs |
Breast Cancer
|
June 2012 | |
| NCT01275677 | National Cancer Institute (NCI)|NRG Oncology |
HER2+Neu Positive|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7
|
January 6, 2011 | Phase 3 |
| NCT00004067 | NSABP Foundation Inc|National Cancer Institute (NCI) |
Breast Cancer
|
February 2000 | Phase 3 |
| NCT00398489 | Technical University of Munich|National Cancer Institute (NCI) |
Breast Cancer
|
October 2006 | Phase 2 |
| NCT02000882 | US Oncology Research|Novartis Pharmaceuticals |
Brain Metastases|Breast Cancer|Metastatic Breast Cancer
|
May 29, 2014 | Phase 2 |
| NCT03321981 | Merus N.V. |
Breast Cancer Metastatic
|
January 15, 2018 | Phase 2 |
| NCT03644186 | ETOP IBCSG Partners Foundation|Pfizer|Hoffmann-La Roche |
Breast Cancer|Estrogen Receptor Positive Tumor|HER2-positive Breast Cancer
|
April 16, 2019 | Phase 2 |
| NCT00146042 | University of Michigan Rogel Cancer Center|Genentech, Inc. |
HER-2 Positive Metastatic Breast Cancer
|
March 1999 | Phase 2 |
| NCT05615818 | UNICANCER|Cancer Research UK & UCL Cancer Trials Centre|Belgian Group of Digestive Oncology|National Cancer Institute, France|Cancer Research UK|Taiho Oncology, Inc.|Servier|Zymeworks Inc.|Accord Healthcare, Inc.|Pierre Fabre Medicament|GlaxoSmithKline Research & Development Limited |
Biliary Tract Neoplasms
|
February 2023 | Phase 3 |
| NCT00258960 | Spanish Breast Cancer Research Group|Schering-Plough |
Breast Cancer
|
February 15, 2006 | Phase 2 |
| NCT02627274 | Hoffmann-La Roche |
Solid Tumor|Breast Cancer|Cancer of Head and Neck
|
December 7, 2015 | Phase 1 |
| NCT03368729 | University of Alabama at Birmingham|Translational Breast Cancer Research Consortium|Tesaro, Inc.|Susan G. Komen Breast Cancer Foundation|Breast Cancer Research Foundation of Alabama|VFoundation |
Metastatic Breast Cancer|HER2 Positive Breast Carcinoma
|
September 6, 2019 | Phase 1|Phase 2 |
| NCT03179904 | Mayo Clinic|National Cancer Institute (NCI) |
Advanced Breast Carcinoma|HER2 Positive Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7
|
September 25, 2017 | Phase 2 |
| NCT00038402 | M.D. Anderson Cancer Center|Genentech, Inc. |
Breast Cancer
|
April 2001 | Phase 3 |
| NCT04486352 | Alliance Foundation Trials, LLC.|Genentech, Inc.|Foundation Medicine|Pfizer |
Endometrial Cancer
|
October 20, 2021 | Phase 1|Phase 2 |
| NCT00951665 | Genentech, Inc. |
Metastatic Breast Cancer
|
August 2009 | Phase 1|Phase 2 |
| NCT04296162 | Fudan University |
Breast Cancer
|
March 1, 2019 | Phase 2 |
| NCT03879577 | University of Chicago |
Breast Cancer|Breast Cancer Female|HER2-positive Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III
|
November 25, 2019 | Phase 2 |
| NCT05560308 | Tianjin Medical University Cancer Institute and Hospital |
HER2&addition; Advanced Breast Cancer Patients Progressing on TKI Therapy
|
September 30, 2022 | Not Applicable |
| NCT00949247 | Case Comprehensive Cancer Center |
Breast Cancer
|
December 2009 | Early Phase 1 |
| NCT01959490 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
|
September 24, 2013 | Phase 2 |
| NCT00297596 | SCRI Development Innovations, LLC|Sanofi |
Breast Cancer
|
February 2006 | Phase 2 |
| NCT05458401 | Daiichi Sankyo, Inc. |
HER2-positive Breast Cancer
|
November 11, 2022 | |
| NCT02102438 | Instituto do Cancer do Estado de São Paulo |
Breast Cancer|HER-2 Positive Breast Cancer
|
April 2014 | Not Applicable |
| NCT05605509 | Canadian Cancer Trials Group|Repare Therapeutics |
Advanced Cancer
|
December 2022 | Phase 2 |
| NCT00054470 | The University of Texas Health Science Center at San Antonio|National Cancer Institute (NCI) |
Breast Cancer
|
December 2002 | Phase 2 |
| NCT00433407 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer|Lung Cancer|Ovarian Cancer|Prostate Cancer|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific
|
August 2005 | Not Applicable |
| NCT01304797 | Merrimack Pharmaceuticals |
Breast Cancer
|
March 2011 | Phase 1 |
| NCT04170595 | Genor Biopharma Co., Ltd. |
HER2-positive Breast Cancer
|
March 28, 2014 | Phase 1|Phase 2 |
| NCT05002127 | ALX Oncology Inc.|Eli Lilly and Company |
Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Gastric Adenocarcinoma
|
January 15, 2022 | Phase 2|Phase 3 |
| NCT02226276 | City of Hope Medical Center|National Cancer Institute (NCI) |
Bone Metastases|HER2-positive Breast Cancer|Liver Metastases|Lung Metastases|Recurrent Breast Cancer|Soft Tissue Metastases|Stage IV Breast Cancer
|
January 7, 2015 | Not Applicable |
| NCT00003992 | National Cancer Institute (NCI) |
Breast Cancer
|
August 1999 | Phase 2 |
| NCT01242449 | Vejle Hospital |
Breast Cancer
|
November 2010 | Phase 2 |
| NCT02167854 | Memorial Sloan Kettering Cancer Center|Novartis |
Breast Cancer
|
June 16, 2014 | Phase 1 |
| NCT00943670 | Genentech, Inc. |
Metastatic Breast Cancer
|
July 2009 | Phase 2 |
| NCT01106898 | University of Nebraska|National Cancer Institute (NCI) |
Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer
|
March 2010 | Phase 2 |
| NCT00392392 | SCRI Development Innovations, LLC|Celgene Corporation|Genentech, Inc. |
Breast Cancer
|
October 2006 | Phase 2 |
| NCT04760431 | Second Affiliated Hospital, School of Medicine, Zhejiang University|Peking University International Hospital|Sun Yat-sen University|Zhejiang University |
HER2-positive Breast Cancer|Brain Metastases
|
October 1, 2021 | Phase 2 |
| NCT01998906 | Hoffmann-La Roche |
Breast Cancer
|
May 2002 | Phase 3 |
| NCT01384253 | Orano Med LLC |
Breast Neoplasms|Peritoneal Neoplasms|Ovarian Neoplasms|Pancreatic Neoplasms|Stomach Neoplasms
|
July 2011 | Phase 1 |
| NCT01746771 | Hanmi Pharmaceutical Company Limited|National OncoVenture |
HER-2 Positive Advanced Gastric Cancer
|
November 2012 | Phase 1|Phase 2 |
| NCT02748213 | Hoffmann-La Roche |
Breast Cancer
|
February 2002 | Phase 2 |
| NCT02657343 | Dana-Farber Cancer Institute|Novartis |
Breast Cancer
|
March 9, 2016 | Phase 1|Phase 2 |
| NCT00118053 | University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Aventis Pharmaceuticals|Rutgers, The State University of New Jersey |
Breast Cancer
|
April 2005 | Phase 2 |
| NCT03588533 | Sung Yong Oh|Celltrion|Dong-A University Hospital |
HER-2 Positive Gastric Cancer|Metastatic Cancer
|
June 10, 2018 | Phase 2 |
| NCT03013218 | ALX Oncology Inc. |
Metastatic Cancer|Solid Tumor|Advanced Cancer|NonHodgkin Lymphoma
|
February 3, 2017 | Phase 1 |
| NCT05063786 | Spanish Breast Cancer Research Group|ETOP IBCSG Partners Foundation|Breast International Group|Novartis Pharmaceuticals |
Advanced Breast Cancer
|
September 14, 2021 | Phase 3 |
| NCT04661150 | Hoffmann-La Roche |
Gastric Cancer|Gastroesophageal Junction Adenocarcinoma
|
March 12, 2021 | Phase 2 |
| NCT03734029 | Daiichi Sankyo, Inc.|Daiichi Sankyo Co., Ltd.|AstraZeneca |
Breast Cancer
|
December 27, 2018 | Phase 3 |
| NCT03390608 | Karolinska Institutet|The Swedish Society of Medicine|The Swedish Breast Cancer Association (BRO)|Swedish Breast Cancer Group |
Breast Cancer
|
January 1, 1977 | |
| NCT04819971 | The First Affiliated Hospital of Zhengzhou University |
Stomach Cancer
|
December 1, 2021 | Phase 2 |
| NCT00129896 | Spanish Breast Cancer Research Group|Cephalon|Sanofi|Hoffmann-La Roche|Amgen |
Breast Cancer
|
January 2004 | Phase 1|Phase 2 |
| NCT00550771 | Merck Sharp & Dohme LLC |
Breast Neoplasm
|
July 16, 2007 | Phase 2 |
| NCT00912340 | Emory University|Genentech, Inc.|Novartis Pharmaceuticals |
Breast Cancer
|
May 2009 | Phase 2 |
| NCT03845270 | Intergroupe Francophone de Cancerologie Thoracique |
Non Small Cell Lung Cancer Metastatic|Non Small Cell Lung Cancer Stage III|HER2 Gene Mutation
|
May 17, 2019 | Phase 2 |
| NCT00637325 | Regione Lombardia|Mario Negri Institute for Pharmacological Research|Istituto Clinico Humanitas |
Metastatic or Locally Advanced Breast Cancer
|
November 2007 | Phase 3 |
| NCT01480583 | Angiochem Inc |
Breast Cancer|Brain Metastases
|
October 2011 | Phase 2 |
| NCT00493649 | US Oncology Research|Sanofi |
Breast Cancer
|
June 2007 | Phase 2 |
| NCT00769379 | National Cancer Institute (NCI)|NRG Oncology |
Breast Ductal Carcinoma In Situ
|
November 10, 2008 | Phase 3 |
| NCT03726879 | Hoffmann-La Roche|Chugai Pharmaceutical |
Breast Cancer
|
January 11, 2019 | Phase 3 |
| NCT02678182 | Royal Marsden NHS Foundation Trust|MedImmune LLC|Clovis Oncology, Inc.|Eli Lilly and Company |
Adenocarcinoma of the Oesophagus|Adenocarcinoma of the Gastro-oesophageal Junction|Adenocarcinoma of the Stomach
|
February 2015 | Phase 2 |
| NCT04108858 | National Cancer Institute (NCI) |
Anatomic Stage IV Breast Cancer AJCC v8|HER2-Positive Breast Carcinoma|Metastatic Breast Carcinoma
|
December 6, 2019 | Phase 1|Phase 2 |
| NCT05113251 | AstraZeneca|Daiichi Sankyo, Inc. |
Breast Neoplasms|Breast Cancer|HER2-positive Early Breast Cancer
|
October 25, 2021 | Phase 3 |
| NCT02320435 | Hoffmann-La Roche |
Solid Tumor
|
February 2, 2015 | Phase 3 |
| NCT01937117 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Translational Breast Cancer Research Consortium|Genentech, Inc. |
Breast Cancer
|
January 30, 2014 | Phase 2 |
| NCT03153163 | Hoffmann-La Roche |
Breast Neoplasms
|
June 20, 2017 | Phase 1 |
| NCT02586025 | Hoffmann-La Roche |
Breast Cancer
|
March 14, 2016 | Phase 3 |
| NCT03368131 | Hebei Medical University |
Gastroesophageal Junction Adenocarcinoma
|
December 1, 2017 | Phase 2 |
| NCT00674414 | UNICANCER |
Breast Cancer
|
April 2008 | Phase 2 |
| NCT00138125 | Translational Oncology Research International|University of California, Los Angeles|Genentech, Inc.|AstraZeneca |
Breast Cancer
|
April 2005 | Phase 2 |
| NCT00003740 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Prostate Cancer
|
October 1998 | Phase 2 |
| NCT01940497 | Hoffmann-La Roche |
Breast Cancer
|
November 15, 2013 | Phase 3 |
| NCT00320385 | GlaxoSmithKline |
Neoplasms, Breast
|
November 2005 | Phase 3 |
| NCT05193292 | Fudan University |
Colorectal Neoplasms|Intestinal Neoplasms
|
January 2022 | Phase 2 |
| NCT03272477 | Palleos Healthcare GmbH|Roche Pharma AG|WSG WOMEN´S HEALTHCARE STUDY GROUP|Cankado GmbH |
Breast Neoplasms
|
October 5, 2017 | Phase 2 |
| NCT01485926 | Cancer Trials Ireland |
Breast Cancer
|
October 2010 | Phase 2 |
| NCT01228045 | National University Hospital, Singapore|National Cancer Centre, Singapore |
Gastric Cancer
|
February 2011 | Phase 2 |
| NCT03334617 | AstraZeneca |
Non-Small Cell Lung Cancer
|
December 18, 2017 | Phase 2 |
| NCT05420454 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Breast Cancer
|
July 10, 2022 | Phase 4 |
| NCT02738970 | Hoffmann-La Roche |
Early Breast Cancer
|
June 23, 2016 | Phase 1 |
| NCT01904903 | Medstar Health Research Institute|Genentech, Inc. |
HER2 Positive Breast Cancer|Left Ventricular Function Systolic Dysfunction
|
October 2013 | Phase 2 |
| NCT00004888 | National Cancer Institute (NCI) |
Recurrent Breast Cancer|Stage IV Breast Cancer
|
January 2001 | Phase 2 |
| NCT00057993 | Northwestern University|National Cancer Institute (NCI) |
Breast Cancer
|
July 2002 | Phase 2 |
| NCT01894711 | Maastricht University Medical Center |
Breast Cancer
|
May 2010 | |
| NCT00817362 | Infinity Pharmaceuticals, Inc. |
Breast Cancer|HER2 Positive Breast Cancer|Metastatic Breast Cancer|Cancer of the Breast
|
March 2009 | Phase 2 |
| NCT04670796 | Shanghai Henlius Biotech |
Healthy
|
March 2, 2021 | Phase 1 |
| NCT00216073 | Hoosier Cancer Research Network|Sanofi|Hoffmann-La Roche|Walther Cancer Institute |
Metastatic Breast Cancer
|
March 2004 | Phase 2 |
| NCT02689921 | Midwestern Regional Medical Center |
Breast Neoplasms
|
April 2016 | Phase 2 |
| NCT02726399 | Memorial Sloan Kettering Cancer Center |
Gastric Cancer|Gastroesophageal Junction Cancer
|
March 18, 2016 | Phase 2 |
| NCT00258349 | National Cancer Institute (NCI) |
Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
August 2006 | Phase 1|Phase 2 |
| NCT01401166 | Hoffmann-La Roche |
Breast Neoplasms
|
October 2011 | Phase 2 |
| NCT02789657 | Brown University|Women and Infants Hospital of Rhode Island|Rhode Island Hospital|The Miriam Hospital |
Breast Cancer
|
November 21, 2016 | Phase 2 |
| NCT04307329 | The Netherlands Cancer Institute|AstraZeneca |
Breast Cancer
|
March 23, 2021 | Phase 2 |
| NCT00130507 | Spanish Breast Cancer Research Group|Hoffmann-La Roche |
Breast Cancer
|
November 4, 2005 | Phase 2 |
| NCT02238509 | Consorzio Oncotech|Clinical Research Technology S.r.l. |
Metastatic Breast Cancer
|
November 2014 | Phase 2 |
| NCT01817452 | West German Study Group|Roche Pharma AG |
Breast Cancer
|
March 2014 | Phase 2 |
| NCT00041067 | Southwest Oncology Group|National Cancer Institute (NCI) |
Breast Cancer
|
September 2002 | Phase 2 |
| NCT00807859 | Amgen |
Breast Cancer|Breast Neoplasms|Breast Tumors|Cancer|Locally Recurrent and Metastatic Breast Cancer|Metastases|Metastatic Cancer|Oncology|Solid Tumors|Tumors
|
March 9, 2009 | Phase 1 |
| NCT02510781 | Hospital Affiliated to Military Medical Science, Beijing |
Breast Neoplasms
|
January 2015 | Phase 2 |
| NCT03199300 | University Medical Center Groningen |
Toxicity Due to Chemotherapy|Cardiovascular Morbidity|Cancer, Treatment-Related
|
December 12, 2017 | |
| NCT05188495 | Peking University Cancer Hospital & Institute |
HER2-positive Metastatic Breast Cancer|Previously Treated With Trastuzumab|Trastuzumab Combined With Pertuzumab and Chemotherapy
|
May 10, 2021 | |
| NCT02665637 | Celltrion |
Healthy Volunteers
|
December 2015 | Phase 1 |
| NCT04494425 | AstraZeneca|Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo |
Advanced or Metastatic Breast Cancer
|
July 24, 2020 | Phase 3 |
| NCT05395052 | Fate Therapeutics |
Non Small Cell Lung Cancer|Colorectal Cancer|Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Head and Neck Cancer|GastroEsophageal Cancer
|
May 31, 2022 | Phase 1 |
| NCT01196390 | National Cancer Institute (NCI)|NRG Oncology |
Esophageal Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Stage IB Esophageal Cancer AJCC v7|Stage IIA Esophageal Cancer AJCC v7|Stage IIB Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer AJCC v7
|
December 30, 2010 | Phase 3 |
| NCT03931551 | MedSIR |
Advanced Breast Cancer
|
April 30, 2019 | Phase 2 |
| NCT02593708 | Michelle Melisko|University of California, San Francisco |
Solid Tumor
|
November 3, 2015 | Phase 1 |
| NCT00687440 | Merck Sharp & Dohme LLC|MDS Pharma Services |
Breast Neoplasm
|
July 15, 2005 | Phase 2 |
| NCT01690325 | West German Study Group|Roche Pharma AG|Sanofi |
Breast Cancer
|
September 2012 | Phase 2 |
| NCT01363986 | Hoffmann-La Roche |
Breast Cancer
|
September 2011 | Phase 2 |
| NCT04253561 | SOLTI Breast Cancer Research Group|Roche Pharma AG |
Metastatic Breast Cancer
|
February 25, 2020 | Phase 1 |
| NCT00003797 | Brown University|National Cancer Institute (NCI) |
Pancreatic Cancer
|
March 1999 | Phase 2 |
| NCT04158856 | xuexin he|Second Affiliated Hospital, School of Medicine, Zhejiang University |
HER2-positive Breast Cancer
|
June 1, 2020 | Phase 2 |
| NCT02901301 | Yonsei University |
Gastric Cancer
|
February 6, 2017 | Phase 1|Phase 2 |
| NCT00146549 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Brigham and Women´s Hospital|North Shore Medical Center|GlaxoSmithKline |
Breast Cancer|Stage IV Breast Cancer
|
August 2001 | Phase 3 |
| NCT01774786 | Hoffmann-La Roche |
Gastric Cancer
|
June 10, 2013 | Phase 3 |
| NCT01191697 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Genentech, Inc. |
Esophageal Cancer|Gastric Cancer
|
February 2011 | Phase 2 |
| NCT04499924 | Seagen Inc. |
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Esophageal Adenocarcinoma
|
March 22, 2021 | Phase 2|Phase 3 |
| NCT00284180 | SCRI Development Innovations, LLC|Bristol-Myers Squibb |
Breast Neoplasms|Breast Cancer
|
January 2006 | Phase 2 |
| NCT01132664 | Novartis Pharmaceuticals|Novartis |
Metastatic Breast Cancer|HER2&addition; Breast Cancer
|
May 2010 | Phase 1|Phase 2 |
| NCT01748773 | Hoffmann-La Roche |
Gastric Cancer|Gastroesophageal Junction Cancer
|
January 29, 2013 | Phase 2 |
| NCT04553770 | Jonsson Comprehensive Cancer Center|Translational Research in Oncology-U.S|Daiichi Sankyo Co., Ltd. |
Early-stage Breast Cancer|Hormone Receptor Positive Breast Carcinoma|Invasive Breast Cancer|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer
|
October 9, 2020 | Phase 2 |
| NCT01295086 | Odense University Hospital|Aalborg University Hospital|Aarhus University Hospital|Rigshospitalet, Denmark |
Adenocarcinoma
|
March 2011 | Not Applicable |
| NCT03674112 | Hoffmann-La Roche |
HER2-Positive Early Breast Cancer
|
December 19, 2018 | Phase 2 |
| NCT02569489 | HUYABIO International, LLC. |
Breast Cancer
|
December 2015 | Phase 1 |
| NCT00004013 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
January 1999 | Phase 2 |
| NCT00429299 | GlaxoSmithKline |
Neoplasms, Breast
|
August 2006 | Phase 2 |
| NCT05152147 | Zymeworks Inc.|BeiGene, Ltd. |
Gastric Neoplasms|Gastroesophageal Adenocarcinoma|Esophageal Adenocarcinoma
|
December 2, 2021 | Phase 3 |
| NCT02771795 | Samsung Bioepis Co., Ltd. |
Breast Neoplasms
|
April 2016 | |
| NCT02004769 | Sun Yat-sen University|Fudan University|307 Hospital of PLA|Shandong Tumor Hospital|Tongji Hospital|West China Hospital|Shandong Provincial Hospital|Second Affiliated Hospital of Suzhou University|Tianjin Medical University General Hospital|Second Affiliated Hospital, School of Medicine, Zhejiang University|Sixth Affiliated Hospital, Sun Yat-sen University|Nanfang Hospital of Southern Medical University |
Stomach Neoplasms|Neoplasms Metastasis|ERBB2 Gene Amplification
|
November 2013 | Phase 2 |
| NCT04591431 | Fondazione per la Medicina Personalizzata |
Breast Cancer|Gastrointestinal Cancer|Non Small Cell Lung Cancer|Other Cancer
|
October 7, 2020 | Phase 2 |
| NCT00679341 | Hoffmann-La Roche |
Breast Cancer
|
September 2008 | Phase 2 |
| NCT00238420 | National Cancer Institute (NCI)|Radiation Therapy Oncology Group |
Bladder Urothelial Carcinoma|Stage I Bladder Cancer AJCC v6 and v7|Stage II Bladder Cancer AJCC v6 and v7|Stage III Bladder Cancer AJCC v6 and v7
|
July 26, 2005 | Phase 1|Phase 2 |
| NCT04683445 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Breast Cancer
|
December 1, 2020 | |
| NCT01730833 | City of Hope Medical Center|National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Breast Adenocarcinoma|Inflammatory Breast Carcinoma
|
July 17, 2013 | Phase 2 |
| NCT05346861 | Fudan University |
HER2-positive Breast Cancer|Metastatic Breast Cancer
|
September 15, 2021 | Phase 3 |
| NCT03529110 | Daiichi Sankyo, Inc.|Daiichi Sankyo Co., Ltd.|AstraZeneca |
Breast Cancer
|
August 9, 2018 | Phase 3 |
| NCT02735798 | Pamela Munster|University of California, San Francisco |
Brain Metastases|Documented Her2 Overexpression|Advanced Solid Tumor|Neurologically Stable
|
April 2016 | Early Phase 1 |
| NCT02843126 | Fuda Cancer Hospital, Guangzhou|Shenzhen Hank Bioengineering Institute |
Recurrent Breast Cancer
|
July 1, 2016 | Phase 1|Phase 2 |
| NCT05170256 | Morten Mau-Sørensen|Odense University Hospital|Aalborg University Hospital|Aarhus University Hospital|Rigshospitalet, Denmark |
Esophageal Squamous Cell Carcinoma|HER-2 Protein Overexpression|HER-2 Gene Amplification
|
February 4, 2022 | Phase 2 |
| NCT01969643 | Seagen Inc. |
HER2 Positive Breast Neoplasms|Hormone Receptor Positive Breast Neoplasms|Triple Negative Breast Neoplasms|HER2 Mutations Breast Neoplasms
|
October 22, 2013 | Phase 1 |
| NCT00712881 | Cephalon, Inc.|Teva Branded Pharmaceutical Products R&D, Inc. |
Breast Cancer
|
October 13, 2008 | Phase 2 |
| NCT00140140 | Celgene |
Stage IV (Metastatic) Breast Cancer
|
August 2005 | Phase 1|Phase 2 |
| NCT03414658 | Adrienne G. Waks|Pfizer|Breast Cancer Research Foundation|Johns Hopkins University|Dana-Farber Cancer Institute |
Breast Cancer
|
June 21, 2018 | Phase 2 |
| NCT02376413 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Local Recurrence of Malignant Tumor of Breast
|
March 2015 | |
| NCT00270894 | Accelerated Community Oncology Research Network|Aventis Pharmaceuticals |
Breast Neoplasm
|
November 2005 | Phase 2 |
| NCT04616560 | National Cancer Institute (NCI) |
Osteosarcoma|Recurrent Osteosarcoma
|
February 1, 2021 | Phase 2 |
| NCT02006667 | Hoffmann-La Roche |
Urinary Tract Cancer
|
January 2001 | Phase 2 |
| NCT00436566 | Mayo Clinic|National Cancer Institute (NCI) |
Breast Cancer|Cardiac Toxicity
|
March 16, 2007 | Phase 2 |
| NCT02805829 | Xuzhou Medical University |
Gastric Cancer
|
January 2017 | Phase 1|Phase 2 |
| NCT04717531 | The First Affiliated Hospital with Nanjing Medical University |
Breast Cancer
|
June 3, 2021 | Phase 2 |
| NCT04398914 | Shanghai Jiao Tong University School of Medicine|Jiangsu HengRui Medicine Co., Ltd. |
Breast Cancer Invasive
|
May 30, 2020 | Phase 2 |
| NCT05020860 | Baylor Breast Care Center |
Breast Cancer|Breast Neoplasm|Breast Cancer Female|Breast Cancer Invasive|Breast Cancer Stage II|Breast Cancer Stage III|Triple Negative Breast Cancer|Hormone Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Triple Negative Breast Neoplasms|Estrogen Receptor-positive Breast Cancer
|
June 15, 2022 | Phase 2 |
| NCT00003881 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lung Cancer
|
May 1999 | Phase 2 |
| NCT04298918 | Hoffmann-La Roche |
Breast Cancer
|
September 23, 2020 | Phase 1|Phase 2 |
| NCT05188313 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Esophageal Cancer|Esophageal Adenocarcinoma
|
March 9, 2022 | Phase 3 |
| NCT00004163 | Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Genentech, Inc. |
Head and Neck Cancer
|
October 1999 | Phase 2 |
| NCT03043313 | Seagen Inc.|National Cancer Institute (NCI)|Academic and Community Cancer Research United |
Metastatic Colorectal Adenocarcinoma
|
June 23, 2017 | Phase 2 |
| NCT01594177 | German Breast Group|Boehringer Ingelheim |
Unilateral HER2 Positive Breast Cancer
|
May 2012 | Phase 2 |
| NCT03199885 | National Cancer Institute (NCI)|NRG Oncology |
Metastatic Breast Adenocarcinoma|Metastatic HER2-Positive Breast Carcinoma|Recurrent Breast Adenocarcinoma|Recurrent HER2-Positive Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Unresectable Breast Carcinoma|Unresectable HER2-Positive Breast Carcinoma
|
March 12, 2019 | Phase 3 |
| NCT00964704 | Hoffmann-La Roche |
Breast Cancer
|
March 2011 | Phase 2 |
| NCT01702571 | Hoffmann-La Roche |
Breast Cancer
|
November 27, 2012 | Phase 3 |
| NCT00954512 | Merck Sharp & Dohme LLC |
Neoplasms
|
September 25, 2009 | Phase 1|Phase 2 |
| NCT03125928 | Fox Chase Cancer Center|Genentech, Inc. |
HER2-positive Breast Cancer
|
June 13, 2017 | Phase 2 |
| NCT02091960 | Astellas Pharma Global Development, Inc.|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.|Astellas Pharma Inc |
HER2 Amplified|Advanced Breast Cancer|Human Epidermal Growth Factor Receptor 2 (HER2)
|
August 28, 2014 | Phase 2 |
| NCT05091528 | Silverback Therapeutics |
HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Colorectal Cancer|HER2-expressing Non-small Cell Lung Cancer
|
February 8, 2022 | Phase 1|Phase 2 |
| NCT00639366 | Anglo Celtic Cooperative Oncology Group|National Cancer Institute (NCI) |
Breast Cancer
|
February 2007 | Phase 3 |
| NCT04739761 | AstraZeneca|Daiichi Sankyo, Inc. |
Breast Cancer
|
June 22, 2021 | Phase 3 |
| NCT00875238 | Vanderbilt University|National Cancer Institute (NCI)|Vanderbilt University Medical Center |
Breast Cancer|Cardiac Toxicity|Cardiovascular Complications
|
June 2008 | |
| NCT01674062 | Hoffmann-La Roche |
Breast Cancer
|
May 2006 | Phase 2 |
| NCT00934856 | Hoffmann-La Roche |
Breast Cancer
|
July 2009 | Phase 1|Phase 2 |
| NCT04958486 | The University of Texas Health Science Center, Houston |
Fossa Ependymoma
|
July 8, 2021 | Early Phase 1 |
| NCT03747120 | University of Texas Southwestern Medical Center|Merck Sharp & Dohme LLC |
HER2-positive Breast Cancer|Breast Cancer
|
January 25, 2019 | Phase 2 |
| NCT05555251 | BioInvent International AB |
HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Metastatic Breast Cancer|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Gastric Adenocarcinoma
|
July 28, 2022 | Phase 1|Phase 2 |
| NCT00520975 | National Cancer Institute (NCI) |
Breast Carcinoma|Recurrent Breast Carcinoma|Stage IV Breast Cancer
|
November 2007 | Phase 3 |
| NCT02030561 | National University Hospital, Singapore|National University, Singapore |
Breast Cancer|Gastric Cancer
|
January 2014 | Phase 1|Phase 2 |
| NCT02040935 | Hoffmann-La Roche |
Breast Cancer
|
February 21, 2014 | Phase 3 |
| NCT01300962 | UNC Lineberger Comprehensive Cancer Center|Novartis Pharmaceuticals |
Metastatic Breast Cancer
|
August 2011 | Phase 1 |
| NCT01566721 | Hoffmann-La Roche |
Breast Neoplasms
|
May 17, 2012 | Phase 3 |
| NCT00079326 | National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
January 2004 | Phase 2 |
| NCT01306942 | Spanish Breast Cancer Research Group|Bristol-Myers Squibb |
Metastatic Breast Cancer
|
July 2011 | Phase 1|Phase 2 |
| NCT03811418 | iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|Amgen |
Advanced Breast Cancer|HER2-positive Breast Cancer
|
January 2019 | Phase 3 |
| NCT00820222 | Novartis Pharmaceuticals|Novartis |
Metastases, Brain
|
April 14, 2009 | Phase 3 |
| NCT01386580 | BBB-Therapeutics B.V. |
Brain Metastases|Lung Cancer|Breast Cancer|Melanoma|Malignant Glioma
|
July 2011 | Phase 1|Phase 2 |
| NCT00194779 | University of Washington|National Cancer Institute (NCI) |
Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
October 2003 | Phase 2 |
| NCT00712140 | Warwick Medical School|National Cancer Institute (NCI) |
Breast Cancer
|
October 2007 | Phase 3 |
| NCT04893109 | Dana-Farber Cancer Institute|Genentech, Inc. |
Breast Cancer|HER2-positive Breast Cancer
|
June 16, 2021 | Phase 2 |
| NCT01679743 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Breast Cancer|Lung Neoplasms|Breast Neoplasms|Lung Cancer
|
August 29, 2012 | Phase 2 |
| NCT00086957 | City of Hope Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
January 2004 | Phase 1|Phase 2 |
| NCT02120911 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Roche Pharma AG |
Esophageal Carcinoma
|
January 2014 | Phase 1|Phase 2 |
| NCT01959386 | Hoffmann-La Roche |
Breast Neoplasms
|
November 7, 2013 | |
| NCT03379428 | US Oncology Research|AbbVie|Pharmacyclics LLC. |
Breast Neoplasms|Malignant Neoplasm of Breast
|
November 29, 2017 | Phase 1|Phase 2 |
| NCT00795678 | Case Comprehensive Cancer Center|United States Department of Defense|National Cancer Institute (NCI) |
Breast Cancer|Metastatic Cancer
|
September 2008 | |
| NCT01260194 | Hoffmann-La Roche |
Gastric Cancer
|
June 2011 | Phase 4 |
| NCT05388500 | Institut de cancérologie Strasbourg Europe |
HER2-positive Breast Cancer
|
December 15, 2022 | Phase 3 |
| NCT01205217 | GlaxoSmithKline |
Neoplasms, Breast
|
December 2010 | Phase 2 |
| NCT00950300 | Hoffmann-La Roche |
Breast Cancer
|
October 16, 2009 | Phase 3 |
| NCT00486668 | NSABP Foundation Inc|GlaxoSmithKline |
Invasive Breast Cancer
|
July 2007 | Phase 3 |
| NCT02318901 | Western Regional Medical Center |
Advanced Cancer|Breast Cancer|Gastric Cancer|Esophageal Cancer|Colorectal Cancer
|
October 2014 | Phase 1|Phase 2 |
| NCT00864175 | Incyte Corporation |
Breast Cancer
|
July 2007 | Phase 1|Phase 2 |
| NCT01891357 | West German Study Group|GlaxoSmithKline |
Carcinoma, Ductal, Breast
|
September 30, 2013 | Phase 2 |
| NCT02774681 | Northwestern University|Pfizer|National Cancer Institute (NCI) |
Breast Carcinoma Metastatic in the Brain|Estrogen Receptor Negative|HER2+Neu Negative|HER2+Neu Positive|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer
|
August 31, 2016 | Phase 2 |
| NCT01084876 | Celltrion |
Metastatic Breast Cancer
|
June 2010 | Phase 3 |
| NCT02149524 | Samsung Bioepis Co., Ltd. |
HER2 Positive Early or Locally Advanced Breast Cancer
|
April 2014 | Phase 3 |
| NCT03878524 | OHSU Knight Cancer Institute|Oregon Health and Science University |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Anatomic Stage IV Breast Cancer AJCC v8|Anemia|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Castration-Resistant Prostate Carcinoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid System Neoplasm|Locally Advanced Pancreatic Adenocarcinoma|Metastatic Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Pancreatic Adenocarcinoma|Myelodysplastic+Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable|Primary Myelofibrosis|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Myelodysplastic+Myeloproliferative Neoplasm|Recurrent Myeloproliferative Neoplasm|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelomonocytic Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Myelodysplastic Syndrome|Refractory Myelodysplastic+Myeloproliferative Neoplasm|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Unresectable Pancreatic Adenocarcinoma
|
April 1, 2020 | Phase 1 |
| NCT00717405 | Hoffmann-La Roche |
Breast Cancer
|
October 2008 | Phase 2 |
| NCT04181333 | Pfizer |
Gastric Cancer
|
November 30, 2022 | |
| NCT02091141 | Genentech, Inc. |
Neoplasms|Solid Tumors|Biliary Cancer|Salivary Cancer|Bladder Cancer
|
April 14, 2014 | Phase 2 |
| NCT01771458 | Institut Curie |
Reccurent+Metastatic Solid Tumor Disease
|
October 2012 | Phase 2 |
| NCT05187182 | Washington University School of Medicine|Curis, Inc. |
Gastric Cancer|Esophageal Cancer|Stomach Cancer|Esophagus Cancer|Gastroesophageal Junction Cancer
|
November 30, 2022 | Phase 1 |
| NCT02297698 | Cancer Insight, LLC|Genentech, Inc.|Sellas Life Sciences Group |
Breast Cancer
|
October 2014 | Phase 2 |
| NCT03262935 | Byondis B.V. |
Metastatic Breast Cancer
|
November 30, 2017 | Phase 3 |
| NCT03135171 | University of Michigan Rogel Cancer Center |
Breast Cancer
|
July 26, 2017 | Phase 1 |
| NCT00681993 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Breast Cancer Research Foundation |
Breast Cancer
|
April 2008 | Not Applicable |
| NCT00896376 | Centre Antoine Lacassagne |
Breast Cancer
|
December 2005 | Not Applicable |
| NCT02488564 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
HER-2 Positive Breast Cancer
|
December 17, 2014 | Phase 2 |
| NCT00182793 | City of Hope Medical Center|National Cancer Institute (NCI) |
Breast Cancer
|
July 2005 | Phase 2 |
| NCT02213042 | Novartis Pharmaceuticals|Novartis |
Neoplasms, Breast
|
October 24, 2014 | Phase 2 |
| NCT04588545 | H. Lee Moffitt Cancer Center and Research Institute|Genentech, Inc. |
HER2-positive Breast Cancer|Leptomeningeal Metastasis|Leptomeningeal Disease
|
December 10, 2020 | Phase 1|Phase 2 |
| NCT00006089 | National Cancer Institute (NCI)|Gynecologic Oncology Group |
Endometrial Adenocarcinoma|ERBB2 Gene Amplification|Recurrent Uterine Corpus Carcinoma|Stage III Uterine Corpus Cancer AJCC v7|Stage IV Uterine Corpus Cancer AJCC v7
|
September 18, 2000 | Phase 2 |
| NCT04487236 | Suzhou Zanrong Pharma Limited |
Advanced Solid Tumors|HER2-positive Breast Cancer
|
October 15, 2020 | Phase 1 |
| NCT00093808 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Breast Cancer
|
August 2004 | Phase 2 |
| NCT00796978 | Cynthia Owusu, MD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center |
Breast Cancer
|
November 11, 2008 | Phase 2 |
| NCT02060253 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Synta Pharmaceuticals Corp.|New York University Cancer Institute |
HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
April 2014 | Phase 1 |
| NCT04301375 | David Garcia Cinca|Fundacion Clinic per a la Recerca Biomédica|Hospital Clinic of Barcelona |
Mammary Cancer
|
June 15, 2020 | Phase 2 |
| NCT04579380 | Seagen Inc. |
Uterine Neoplasms|Uterine Cervical Neoplasms|Biliary Tract Neoplasms|Urologic Neoplasms|Carcinoma, Non-Small-Cell Lung|HER2 Mutations Breast Neoplasms
|
January 11, 2021 | Phase 2 |
| NCT04733118 | MedSIR|Hoffmann-La Roche |
Early Breast Cancer
|
August 5, 2021 | Phase 2 |
| NCT02638428 | Samsung Medical Center|Ministry of Health, Republic of Korea |
Relapsed Pediatric Solid Tumor|Refractory Pediatric Solid Tumor|Relapsed Pediatric AML|Refractory Pediatric AML
|
December 2015 | Phase 2 |
| NCT00193076 | SCRI Development Innovations, LLC|Eli Lilly and Company|Genentech, Inc. |
Breast Cancer
|
November 2003 | Phase 2 |
| NCT00005970 | National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|Canadian Cancer Trials Group|Southwest Oncology Group |
Breast Adenocarcinoma|HER2 Positive Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7
|
May 19, 2000 | Phase 3 |
| NCT00829166 | Hoffmann-La Roche |
Breast Cancer
|
February 2009 | Phase 3 |
| NCT00470847 | Nancy Lin, MD|Brigham and Women´s Hospital|Breast Cancer Research Foundation|GlaxoSmithKline|Dana-Farber Cancer Institute |
Breast Cancer|Brain Metastases
|
April 2007 | Phase 1 |
| NCT00085020 | Jonsson Comprehensive Cancer Center|GlaxoSmithKline |
Breast Cancer
|
March 2004 | Phase 1 |
| NCT04538742 | AstraZeneca|Daiichi Sankyo Company, Limited |
Metastatic Breast Cancer
|
December 28, 2020 | Phase 1|Phase 2 |
| NCT04512261 | Reva Basho|Merck Sharp & Dohme LLC|Seagen Inc.|Cedars-Sinai Medical Center |
Breast Cancer|Brain Metastases|HER2-positive Breast Cancer|CNS Disease
|
June 1, 2022 | Phase 1|Phase 2 |
| NCT00104949 | Southwest Oncology Group|National Cancer Institute (NCI) |
Sarcoma
|
July 2005 | Phase 2 |
| NCT00841828 | Spanish Breast Cancer Research Group|GlaxoSmithKline |
Breast Cancer
|
February 2009 | Phase 2 |
| NCT00407888 | University of Washington|National Cancer Institute (NCI) |
Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
May 2006 | Phase 2 |
| NCT02909751 | Vejle Hospital |
Breast Cancer
|
September 14, 2016 | Phase 2 |
| NCT04578106 | Fundacio Clinic Barcelona|SOLTI Breast Cancer Research Group|Roche Pharma AG |
HER2-positive Breast Cancer|Stage I Breast Cancer
|
September 23, 2020 | Phase 2 |
| NCT02571530 | Northwell Health |
Neoplasm Metastasis
|
August 2015 | Phase 1 |
| NCT05426486 | Caigang Liu|NovoCodex Biopharmaceuticals Co., Ltd.|Jiangsu HengRui Medicine Co., Ltd.|Shengjing Hospital |
HER2-positive Breast Cancer
|
May 23, 2022 | Phase 2|Phase 3 |
| NCT04034823 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
HER2-positive Breast Cancer
|
September 1, 2019 | Phase 2 |
| NCT02154529 | Kadmon Corporation, LLC |
HER-2 Positive Breast Cancer|Metastatic Malignant Neoplasm to Brain
|
May 2014 | Phase 1|Phase 2 |
| NCT00201760 | Kari Kendra|Eli Lilly and Company|Ohio State University Comprehensive Cancer Center |
Breast Cancer
|
February 25, 2005 | Phase 2 |
| NCT02693535 | American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme LLC|Pfizer|Boehringer Ingelheim|Seagen Inc. |
Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors
|
March 14, 2016 | Phase 2 |
| NCT00496808 | M.D. Anderson Cancer Center |
Ductal Carcinoma In Situ
|
March 2005 | Not Applicable |
| NCT05143970 | Institut Paoli-Calmettes|Innate Pharma |
Metastatic Cancer|Metastatic Breast Cancer|Metastatic Pancreatic Cancer|Metastatic Gastric Cancer|Metastatic Lung Cancer|Metastatic Ovary Cancer|Oesophageal Cancer|Endometrial Cancer|Advanced Solid Tumor
|
January 26, 2022 | Phase 1 |
| NCT01472029 | AIO-Studien-gGmbH|Roche Pharma AG |
Adenocarcinoma of the Gastroesophageal Junction|Adenocarcinoma of the Stomach
|
December 2011 | Phase 2 |
| NCT00047255 | Jonsson Comprehensive Cancer Center |
Breast Cancer
|
May 2002 | Phase 3 |
| NCT00242203 | Washington University School of Medicine|Novartis|Pfizer |
Breast Neoplasms
|
October 2002 | Phase 2 |
| NCT00971737 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Breast Cancer
|
July 2009 | Phase 2 |
| NCT03766607 | Korean South West Oncology Group |
Gastric Cancer
|
September 30, 2019 | Phase 2 |
| NCT02514681 | Japan Breast Cancer Research Group|Chugai Pharmaceutical |
HER2-positive Locally Advanced or Metastatic Breast Cancer
|
August 1, 2015 | Phase 3 |
| NCT02297230 | NYU Langone Health |
Breast Cancer
|
June 2002 | Phase 1|Phase 2 |
| NCT01471847 | Novartis Pharmaceuticals|Novartis |
Locally Advance Breast Cancer (LABC)|Metastatic Breast Cancer (MBC)
|
February 2012 | Phase 1 |
| NCT00004883 | National Cancer Institute (NCI) |
Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
|
February 2000 | Phase 2 |
| NCT00412412 | Biogen |
Breast Cancer
|
December 2007 | Phase 1 |
| NCT00254592 | University of California, Irvine |
Breast Cancer
|
October 2005 | Phase 2 |
| NCT00450892 | European Organisation for Research and Treatment of Cancer - EORTC|GlaxoSmithKline |
Breast Cancer
|
February 2007 | Phase 1|Phase 2 |
| NCT04439110 | National Cancer Institute (NCI) |
Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma
|
August 12, 2015 | Phase 2 |
| NCT00781612 | Genentech, Inc.|Hoffmann-La Roche |
Neoplasm Metastasis
|
October 16, 2008 | Phase 2 |
| NCT03319459 | Fate Therapeutics |
HER2 Positive Gastric Cancer|Colorectal Cancer|Head and Neck Squamous Cell Carcinoma|EGFR Positive Solid Tumor|Advanced Solid Tumors|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Pancreatic Cancer|Melanoma
|
January 18, 2018 | Phase 1 |
| NCT01187381 | Hoffmann-La Roche |
Breast Cancer
|
April 14, 2010 | |
| NCT02336984 | H. Lee Moffitt Cancer Center and Research Institute |
Breast Cancer
|
June 2014 | Phase 1|Phase 2 |
| NCT01602406 | Novartis Pharmaceuticals|Novartis |
Advanced HER2-positive Breast Cancer or Gastric Cancer
|
September 21, 2012 | Phase 1 |
| NCT02314481 | University College, London|Hoffmann-La Roche |
Non-small Cell Lung Cancer
|
May 12, 2017 | Phase 2 |
| NCT03457896 | NSABP Foundation Inc|Puma Biotechnology, Inc. |
Metastatic Colorectal Cancer
|
May 18, 2018 | Phase 2 |
| NCT04082364 | MacroGenics|Zai Lab (Shanghai) Co., Ltd. |
Gastric Cancer|Gastroesophageal Junction Cancer|HER2-positive Gastric Cancer
|
September 30, 2019 | Phase 2|Phase 3 |
| NCT03698383 | Korean Cancer Study Group |
HER2-positive Breast Cancer|Metastatic Breast Cancer
|
December 3, 2019 | Phase 2 |
| NCT00266110 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)|Susan G. Komen Breast Cancer Foundation |
Breast Cancer
|
December 2005 | Phase 2 |
| NCT03364348 | George W. Sledge Jr.|National Cancer Institute (NCI)|Stanford University |
HER2 Positive Breast Carcinoma|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
October 30, 2017 | Phase 1 |
| NCT04905667 | Genor Biopharma Co., Ltd. |
Breast Cancer
|
November 13, 2019 | Phase 1 |
| NCT00605397 | Memorial Sloan Kettering Cancer Center |
Breast Cancer
|
January 2007 | Phase 1 |
| NCT00088985 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)|Susan G. Komen Breast Cancer Foundation |
Breast Cancer
|
January 2004 | Phase 2 |
| NCT03925233 | Xijing Hospital |
Breast Cancer Organoids
|
January 2, 2019 | |
| NCT04395508 | Genentech, Inc. |
HER2-positive Breast Cancer
|
||
| NCT05319873 | Jonsson Comprehensive Cancer Center|Seagen Inc.|Novartis |
Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Locally Advanced HER2-Positive Breast Carcinoma|Metastatic HER2-Positive Breast Carcinoma|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8
|
April 7, 2022 | Phase 1|Phase 2 |
| NCT02252887 | Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Hoffmann-La Roche|Hartford HealthCare |
Metastatic HER2-Positive Breast Cancer
|
January 12, 2015 | Phase 2 |
| NCT01008150 | NSABP Foundation Inc|Puma Biotechnology, Inc. |
Breast Cancer
|
October 2010 | Phase 2 |
| NCT05020964 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Advanced Breast Cancer
|
August 20, 2021 | Phase 2 |
| NCT01120184 | Hoffmann-La Roche|Genentech, Inc. |
Breast Cancer
|
July 31, 2010 | Phase 3 |
| NCT00148876 | German Breast Group|Hoffmann-La Roche |
Breast Cancer
|
September 2003 | Phase 3 |
| NCT05574881 | Fudan University |
Breast Cancer
|
September 1, 2022 | Phase 1|Phase 2 |
| NCT01491737 | Hoffmann-La Roche |
Breast Cancer
|
February 17, 2012 | Phase 2 |
| NCT05159193 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|CSPC Ouyi Pharmaceutical Co., Ltd. |
Breast Cancer
|
December 20, 2021 | Phase 3 |
| NCT00003440 | National Cancer Institute (NCI) |
HER2-negative Breast Cancer|HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
July 1998 | Phase 3 |
| NCT00960960 | Genentech, Inc. |
Breast Cancer
|
August 2009 | Phase 1 |
| NCT02658084 | University of Miami|Genentech, Inc. |
Breast Cancer|Metastatic Breast Cancer
|
April 12, 2017 | Phase 1|Phase 2 |
| NCT03493854 | Hoffmann-La Roche |
Early Breast Cancer
|
June 14, 2018 | Phase 3 |
| NCT00039455 | National Cancer Institute (NCI) |
HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
|
April 2002 | Phase 1 |
| NCT03910712 | Peking Union Medical College Hospital |
Breast Cancer Female|HER2-positive Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|Metastatic Breast Cancer|Breast Diseases|Hormone Receptor Positive Tumor
|
June 1, 2019 | Phase 2 |
| NCT03239015 | Baodong Qin|Shanghai Changzheng Hospital |
Rare Tumor|Refractory Tumor
|
January 1, 2017 | Phase 2 |
| NCT02598310 | Osaka Medical College |
Breast Cancer|Estrogen Receptor Negative Neoplasm|HER-2 Positive Breast Cancer
|
November 2015 | Phase 2 |
| NCT02654119 | University of Nebraska|National Cancer Institute (NCI) |
HER2 Positive Breast Carcinoma|Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7
|
December 11, 2015 | Phase 2 |
| NCT05515796 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
Immunotherapy|Gastric Cancer|Rectal Cancer|Chemotherapy Effect|Radiotherapy
|
September 1, 2022 | Phase 2 |
| NCT05275010 | Hoffmann-La Roche |
Healthy Male Subjects
|
May 30, 2022 | Phase 1 |
| NCT01450696 | Hoffmann-La Roche |
Gastric Cancer
|
December 2011 | Phase 3 |
| NCT04152057 | West China Hospital|Jiangsu HengRui Medicine Co., Ltd. |
Breast Cancer|HER2 Positive|Combination Chemotherapy
|
November 2019 | Phase 1|Phase 2 |
| NCT02125344 | German Breast Group|Amgen|Roche Pharma AG|Teva Pharmaceuticals USA|Vifor Pharma |
Tubular Breast Cancer Stage II|Tubular Breast Cancer Stage III|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer
|
December 2014 | Phase 3 |
| NCT02445586 | Hoffmann-La Roche |
Breast Cancer
|
August 17, 2015 | Phase 4 |
| NCT00036868 | European Organisation for Research and Treatment of Cancer - EORTC |
Breast Cancer
|
February 2002 | Phase 2 |
| NCT00103233 | Southwest Oncology Group|National Cancer Institute (NCI) |
Breast Cancer
|
December 2004 | Phase 3 |
| NCT04193059 | Fudan University |
Breast Cancer
|
August 1, 2018 | Phase 3 |
| NCT02562378 | MedSIR|Roche Pharma AG|Experior |
Breast Cancer
|
October 2015 | Phase 1 |
| NCT01305941 | UNC Lineberger Comprehensive Cancer Center|Novartis Pharmaceuticals |
HER-2 Positive Breast Cancer
|
September 2011 | Phase 2 |
| NCT00193089 | SCRI Development Innovations, LLC|Aventis Pharmaceuticals|GlaxoSmithKline |
Breast Cancer
|
April 2001 | Phase 2 |
| NCT01387373 | Dorte Nielsen|Herlev Hospital |
Metastatic Breast Cancer|Liver Metastases
|
April 2010 | Phase 2 |
| NCT01480674 | Hoffmann-La Roche |
Breast Cancer
|
March 28, 2011 | |
| NCT05301530 | Nanogen Pharmaceutical Biotechnology Joint Stock Company|Vietstar Biomedical Research|MedProve Inc |
Breast Cancer Metastatic|Breast Cancer Female|Breast Cancer Recurrent
|
May 27, 2019 | Phase 1 |
| NCT00303992 | University of California, San Francisco|National Cancer Institute (NCI) |
Breast Cancer
|
May 2004 | Phase 2 |
| NCT02954536 | Memorial Sloan Kettering Cancer Center |
Esophageal Cancer|Gastric Cancer
|
November 3, 2016 | Phase 2 |
| NCT04236310 | Ruijin Hospital|Jiangsu HengRui Medicine Co., Ltd. |
Breast Cancer|HER2-positive Breast Cancer|ER-positive Breast Cancer
|
January 15, 2020 | Phase 2 |
| NCT00885755 | Hoffmann-La Roche |
Breast Cancer
|
August 13, 2009 | Phase 2 |
| NCT03095352 | Hope Rugo, MD|Mayo Clinic|Johns Hopkins University|Translational Breast Cancer Research Consortium|Massachusetts General Hospital|Merck Sharp & Dohme LLC|University of California, San Francisco |
Breast Cancer|Chest Wall Disease
|
September 2, 2017 | Phase 2 |
| NCT00950742 | Boehringer Ingelheim |
Breast Neoplasms
|
August 2009 | Phase 1 |
| NCT03273595 | Xijing Hospital |
Neoplasms, Breast
|
July 2016 | Phase 2 |
| NCT02000596 | University of Maryland, Baltimore|Genentech, Inc. |
Metastatic Breast Cancer
|
January 2014 | Phase 2 |
| NCT00005831 | National Cancer Institute (NCI) |
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Bladder Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Squamous Cell Carcinoma of the Bladder|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder
|
March 2000 | Phase 2 |
| NCT02380131 | Hebei Medical University |
HER-2 Positive Gastric Cancer|Liver Metastasis
|
February 2013 | Phase 4 |
| NCT04380012 | Second Affiliated Hospital, School of Medicine, Zhejiang University|Zhejiang Cancer Hospital|Zhejiang Provincial People´s Hospital|First Affiliated Hospital of Zhejiang University|Sir Run Run Shaw Hospital |
Colorectal Cancer
|
December 17, 2019 | Phase 2 |
| NCT00151034 | University of Michigan Rogel Cancer Center|Genentech, Inc. |
Urologic Neoplasms
|
September 2000 | Phase 2 |
| NCT02144012 | Hoffmann-La Roche |
Metastatic Breast Cancer
|
June 2014 | Phase 3 |
| NCT02907918 | Washington University School of Medicine|Pfizer|Rising Tide Foundation |
Breast Cancer|Cancer of Breast|Breast Carcinoma
|
June 30, 2017 | Phase 2 |
| NCT00629278 | Azienda Ospedaliero-Universitaria di Modena|National Cancer Institute (NCI) |
Breast Cancer
|
December 2007 | Phase 3 |
| NCT05246514 | AstraZeneca|Daiichi Sankyo, Inc. |
HER2-mutant Non-Small Cell Lung Cancer
|
July 13, 2022 | Phase 2 |
| NCT01359397 | The Netherlands Cancer Institute |
Metastatic Gastric Cancer|Adenocarcinoma of the Gastro-oesophageal Junction
|
March 2011 | Phase 2 |
| NCT02005484 | Hoffmann-La Roche |
Gastric Cancer
|
January 2004 | Phase 2 |
| NCT00381901 | National Cancer Institute, France|National Cancer Institute (NCI) |
Breast Cancer
|
May 2006 | Phase 3 |
| NCT00800436 | Hoffmann-La Roche |
Breast Cancer
|
November 2008 | Phase 1 |
| NCT00006015 | National Cancer Institute (NCI) |
Colorectal Cancer
|
May 2000 | Phase 2 |
| NCT03571633 | Centre Leon Berard|Amgen |
HER2-positive Breast Cancer|Operable Breast Cancer
|
August 6, 2018 | Phase 2 |
| NCT05525858 | Seoul National University Bundang Hospital|Korean Cancer Study Group|Roche Pharma AG |
Solid Tumor|Advanced Solid Tumor|Metastatic Cancer
|
September 28, 2022 | |
| NCT01097460 | Merrimack Pharmaceuticals |
Breast Neoplasms
|
April 2010 | Phase 1 |
| NCT02015676 | Hoffmann-La Roche |
Breast Cancer
|
July 2001 | Phase 1|Phase 2 |
| NCT02578368 | Krankenhaus Nordwest|German Research Foundation|Arbeitsgemeinschaft fur Internistische Onkologie |
Gastric Cancer
|
February 2016 | Phase 3 |
| NCT04367090 | Jiangsu HengRui Medicine Co., Ltd. |
Metastatic Breast Cancer
|
July 7, 2020 | Phase 1 |
| NCT02066532 | Dawn L. Hershman|Incyte Corporation|National Cancer Institute (NCI)|Columbia University |
Metastatic Breast Cancer|Breast Carcinoma|HER-2 Positive Breast Cancer
|
June 2014 | Phase 1|Phase 2 |
| NCT03988036 | West German Study Group|Merck Sharp & Dohme LLC|NanoString Technologies, Inc. |
Breast Cancer
|
August 18, 2020 | Phase 2 |
| NCT00216047 | Hoosier Cancer Research Network|Novartis Pharmaceuticals|Walther Cancer Institute |
Breast Cancer
|
January 2005 | Phase 1|Phase 2 |
| NCT02393248 | Incyte Corporation |
Lung Cancer|Solid Tumor|Gastric Cancer|Urothelial Cancer|Endometrial Cancer|Multiple Myeloma|Myeloproliferative Neoplasms|Breast Cancer|Cholangiocarcinoma|UC|MPN
|
February 27, 2015 | Phase 1|Phase 2 |
| NCT04961307 | Peking University Third Hospital |
Cardiotoxicity|Antitumor Drugs|Breast Cancer|Trastuzumab
|
July 5, 2019 | |
| NCT03756064 | Zhejiang Cancer Hospital |
Breast Cancer|Neoplasm, Breast|Breast Diseases
|
August 1, 2019 | Not Applicable |
| NCT01973660 | SOLTI Breast Cancer Research Group|Novartis |
Breast Cancer
|
October 2013 | Phase 2 |
| NCT01220128 | GlaxoSmithKline |
Neoplasms, Breast
|
April 11, 2011 | Phase 2 |
| NCT00397501 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Breast Cancer|Cognitive+Functional Effects|Drug+Agent Toxicity by Tissue+Organ|Psychosocial Effects of Cancer and Its Treatment
|
October 2013 | Phase 1|Phase 2 |
| NCT00411788 | Yale University|Genentech, Inc. |
Breast Cancer
|
December 2006 | Phase 2 |
| NCT05189067 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
HER2-positive Breast Cancer|Adjuvant Therapy
|
January 31, 2022 | Phase 2|Phase 3 |
| NCT02625441 | Helsinki University Central Hospital |
Breast Cancer
|
December 2015 | Phase 3 |
| NCT02025192 | Seagen Inc. |
HER2 Positive Metastatic Breast Cancers
|
December 31, 2013 | Phase 1 |
| NCT02924883 | Hoffmann-La Roche |
Metastatic Breast Cancer
|
September 26, 2016 | Phase 2 |
| NCT01964391 | Hoffmann-La Roche |
Breast Cancer
|
February 21, 2014 | Phase 3 |
| NCT02073487 | The Methodist Hospital Research Institute|Celgene Corporation|Novartis |
Breast Cancer
|
February 2014 | Phase 2 |
| NCT00629499 | SCRI Development Innovations, LLC|Celgene Corporation |
Breast Cancer
|
April 2008 | Phase 2 |
| NCT00045032 | Hoffmann-La Roche|Breast International Group|European Organisation for Research and Treatment of Cancer - EORTC|NCIC Clinical Trials Group|ETOP IBCSG Partners Foundation |
Breast Cancer
|
November 2001 | Phase 3 |
| NCT03297606 | Canadian Cancer Trials Group|AstraZeneca|Bristol-Myers Squibb|Hoffmann-La Roche|Pfizer|Seagen Inc. |
Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors
|
October 6, 2017 | Phase 2 |
| NCT00927589 | Genentech, Inc. |
Solid Cancers
|
July 2009 | Phase 1 |
| NCT01401959 | SCRI Development Innovations, LLC|Eisai Inc. |
Metastatic Breast Cancer
|
September 23, 2011 | Phase 2 |
| NCT01427244 | Yale University|Genentech, Inc. |
Paget´s Disease of the Vulva
|
August 2011 | Phase 2 |
| NCT01041404 | Hoffmann-La Roche|Chugai Pharmaceutical |
Gastric Cancer
|
September 2005 | Phase 3 |
| NCT02152943 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Advanced Malignant Solid Neoplasm|Estrogen Receptor Positive|HER2+Neu Positive|Postmenopausal|Premenopausal|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Refractory Breast Carcinoma|Refractory Hormone Receptor Positive Breast Carcinoma|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7
|
July 17, 2014 | Phase 1 |
| NCT00272987 | Novartis Pharmaceuticals|Novartis |
Neoplasms, Breast
|
December 13, 2005 | Phase 3 |
| NCT03784599 | The Netherlands Cancer Institute|AstraZeneca|Roche Pharma AG |
Carcinoma, Non-Small-Cell Lung
|
December 18, 2018 | Phase 2 |
| NCT04092673 | Effector Therapeutics |
Solid Tumor, Adult
|
October 25, 2019 | Phase 1|Phase 2 |
| NCT04632992 | Genentech, Inc. |
Advanced Unresectable or Metastatic Solid Malignancy
|
January 13, 2021 | Phase 2 |
| NCT00535509 | King Faisal Specialist Hospital & Research Center |
Breast Cancer
|
June 2007 | Not Applicable |
| NCT00133796 | Mothaffar Rimawi|Genentech, Inc.|Baylor Breast Care Center |
BREAST CANCER
|
October 2001 | Phase 2 |
| NCT00006108 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
August 1999 | Phase 1|Phase 2 |
| NCT00238290 | Swiss Group for Clinical Cancer Research |
Breast Cancer
|
May 2005 | Phase 2 |
| NCT01928290 | Washington University School of Medicine |
Stomach Neoplasms|Esophageal Neoplasms
|
November 8, 2013 | Phase 2 |
| NCT03680560 | Cogent Biosciences, Inc. |
Solid Tumor|HER-2 Protein Overexpression
|
March 13, 2019 | Phase 1 |
| NCT00301730 | National Cancer Institute (NCI) |
Breast Cancer|Metastatic Cancer
|
October 2005 | Phase 1 |
| NCT03588091 | Jiangsu HengRui Medicine Co., Ltd. |
HER2-positive Breast Cancer
|
July 24, 2018 | Phase 3 |
| NCT02307227 | Centro di Riferimento Oncologico - Aviano |
Breast Neoplasms
|
April 2006 | Phase 2 |
| NCT02419742 | Hoffmann-La Roche |
Breast Cancer
|
August 18, 2015 | Phase 4 |
| NCT04704661 | National Cancer Institute (NCI) |
Advanced Breast Carcinoma|Advanced Colon Carcinoma|Advanced Colorectal Carcinoma|Advanced Endometrial Carcinoma|Advanced Gastric Carcinoma|Advanced Gastroesophageal Junction Adenocarcinoma|Advanced Malignant Solid Neoplasm|Advanced Salivary Gland Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|HER2-Positive Breast Carcinoma|Malignant Hepatobiliary Neoplasm|Metastatic Breast Carcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Malignant Solid Neoplasm|Pathologic Stage III Gastric Cancer AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastric Cancer AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastric Cancer AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIC Gastric Cancer AJCC v8|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage III Colon Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Major Salivary Gland Cancer AJCC v8|Stage III Uterine Corpus Cancer AJCC v8|Stage IIIA Colon Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIA Uterine Corpus Cancer AJCC v8|Stage IIIB Colon Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIB Uterine Corpus Cancer AJCC v8|Stage IIIC Colon Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Uterine Corpus Cancer AJCC v8|Stage IIIC1 Uterine Corpus Cancer AJCC v8|Stage IIIC2 Uterine Corpus Cancer AJCC v8|Stage IV Colon Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Major Salivary Gland Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Colon Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Major Salivary Gland Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Colon Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Major Salivary Gland Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8|Stage IVC Colon Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Stage IVC Major Salivary Gland Cancer AJCC v8|Unresectable Colorectal Carcinoma|Unresectable Gastroesophageal Junction Adenocarcinoma|Unresectable Malignant Solid Neoplasm
|
March 5, 2021 | Phase 1 |
| NCT04168931 | AC Camargo Cancer Center |
Gastric Cancer Stage IV
|
January 1, 2020 | Phase 2 |
| NCT00553358 | Novartis Pharmaceuticals|Breast International Group|SOLTI Breast Cancer Research Group|Novartis |
Neoplasms, Breast
|
January 5, 2008 | Phase 3 |
| NCT04024462 | Hoffmann-La Roche |
HER2-positive Early Breast Cancer
|
February 5, 2020 | Phase 3 |
| NCT00618657 | University of California, Irvine|National Institutes of Health (NIH)|National Cancer Institute (NCI) |
Breast Cancer|HER2-negative Breast Cancer|HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
|
February 2008 | Phase 2 |
| NCT04379596 | AstraZeneca|Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo |
Gastric Cancer
|
June 3, 2020 | Phase 2 |
| NCT00944047 | University of Kansas Medical Center|Celgene Corporation |
Breast Cancer
|
July 2009 | Phase 2 |
| NCT02705859 | Cancer Trials Ireland |
HER2 Positive Breast Cancer
|
April 2016 | Phase 1 |
| NCT00189579 | ARCAGY+ GINECO GROUP|Hoffmann-La Roche |
Ovarian Cancer
|
Phase 2 | |
| NCT01358877 | Hoffmann-La Roche|Genentech, Inc.|Breast International Group |
Breast Cancer
|
November 8, 2011 | Phase 3 |
| NCT00399529 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|American Cancer Society, Inc.|Avon Foundation|Cancer Treatment Research Foundation|The Commonwealth Fund|United States Department of Defense|Genentech, Inc. |
Breast Neoplasms
|
September 2006 | Phase 2 |
| NCT04556773 | AstraZeneca|Daiichi Sankyo Co., Ltd.|Daiichi Sankyo Company, Limited |
Metastatic Breast Cancer
|
December 17, 2020 | Phase 1 |
| NCT01816035 | University of Washington|National Cancer Institute (NCI) |
HER2+Neu Positive|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
|
June 2014 | Phase 1 |
| NCT00758134 | Armando Santoro, MD|Istituto Clinico Humanitas |
NON-SMALL CELL LUNG CANCER
|
July 2008 | Phase 2 |
| NCT01042925 | Sanofi |
Breast Cancer|Breast Neoplasms
|
February 2010 | Phase 1|Phase 2 |
| NCT01501487 | Agendia|University of South Florida|University of Miami|Morton Plant Mease Health Care|AdventHealth|Plano Cancer Center|Ohio State University Comprehensive Cancer Center|University of Oklahoma|University of South Alabama |
Breast Cancer
|
October 2011 | Phase 4 |
| NCT04482309 | AstraZeneca|Daiichi Sankyo Co., Ltd. |
Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Rare Tumors
|
August 18, 2020 | Phase 2 |
| NCT05577923 | Fudan University |
Metastatic Breast Cancer
|
November 1, 2022 | Phase 2 |
| NCT01785420 | Dr Rajendra A. Badwe|Tata Memorial Hospital |
Carcinoma Breast Stage I|HER2 Positive Breast Cancer
|
May 2013 | Phase 3 |
| NCT01928615 | Hoffmann-La Roche |
Breast Cancer
|
September 2013 | Phase 2 |
| NCT02162667 | Celltrion|Nippon Kayaku Co., Ltd. |
HER2-positive Carcinoma of Breast
|
June 2014 | Phase 3 |
| NCT00016276 | National Cancer Institute (NCI) |
Cardiac Toxicity|Inflammatory Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer
|
May 2001 | Phase 3 |
| NCT00006104 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
September 1998 | Phase 2 |
| NCT02605915 | Hoffmann-La Roche |
HER2-Positive Metastatic Breast Cancer|HER2-Negative Metastatic Breast Cancer|Locally Advanced or Early Breast Cancer
|
December 31, 2015 | Phase 1 |
| NCT05420467 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Breast Cancer
|
July 10, 2022 | Phase 4 |
| NCT04351230 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Anatomic Stage IV Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8
|
November 11, 2020 | Phase 2 |
| NCT01340430 | Lucia Del Mastro,MD|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy |
HER-2 Positive Breast Cancer
|
March 2011 | Phase 2 |
| NCT01271920 | Novartis Pharmaceuticals|Novartis |
Advanced HER2-positive Breast Cancer
|
September 2010 | Phase 1|Phase 2 |
| NCT00003995 | National Cancer Institute (NCI) |
Colorectal Cancer
|
September 1999 | Phase 2 |
| NCT00803556 | Bristol-Myers Squibb |
Solid Tumor|Breast Cancer
|
January 2006 | Phase 1 |
| NCT00431704 | National Cancer Institute, Naples |
Metastatic Breast Cancer
|
October 2007 | Phase 2 |
| NCT00391092 | Hoffmann-La Roche |
Breast Cancer
|
September 2006 | Phase 3 |
| NCT00833963 | Genentech, Inc. |
Breast Cancer|Pregnancy
|
January 14, 2009 | |
| NCT00426556 | Novartis Pharmaceuticals|Novartis |
Metastatic Breast Cancer
|
July 2007 | Phase 1 |
| NCT02214004 | Gangnam Severance Hospital|Seoul National University Hospital|Severance Hospital|Samsung Medical Center|Asan Medical Center |
Breast Cancer
|
March 2015 | Phase 2 |
| NCT02536339 | Genentech, Inc. |
Metastatic Breast Cancer
|
December 16, 2015 | Phase 2 |
| NCT03994107 | Peking Union Medical College|CSPC Ouyi Pharmaceutical Co., Ltd. |
Breast Cancer
|
October 1, 2019 | Phase 1|Phase 2 |
| NCT05034887 | National Cancer Center Hospital East|Daiichi Sankyo Co., Ltd. |
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
|
January 31, 2022 | Phase 2 |
| NCT00006381 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Breast Cancer
|
June 2000 | Phase 2 |
| NCT00513292 | National Cancer Institute (NCI) |
HER2+Neu Positive|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
|
July 2007 | Phase 3 |
| NCT00398437 | Jules Bordet Institute|National Cancer Institute (NCI) |
Breast Cancer|Metastatic Cancer
|
September 2006 | Not Applicable |
| NCT04900311 | Tianjin Medical University Cancer Institute and Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
HER2&addition; Early or Locally Advanced Breast Cancer
|
May 2021 | Phase 2 |
| NCT02229149 | US Oncology Research|Genentech, Inc. |
Breast Neoplasms|Malignant Tumor of the Breast
|
December 2014 | Phase 2 |
| NCT03367676 | Ruijin Hospital |
Breast Cancer
|
December 30, 2017 | Phase 2 |
| NCT00005857 | City of Hope Medical Center|National Cancer Institute (NCI) |
Prostate Cancer
|
August 2000 | Phase 2 |
| NCT00543504 | M.D. Anderson Cancer Center |
Advanced Cancer
|
October 10, 2007 | Phase 1 |
| NCT04886531 | Ruth O´Regan|Puma Biotechnology, Inc.|University of Rochester|Hoosier Cancer Research Network |
Breast Cancer|HER2-positive Breast Cancer|ER Positive Breast Cancer|PR-Positive Breast Cancer
|
July 21, 2022 | Phase 2 |
| NCT02658734 | Hoffmann-La Roche |
HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
|
November 1, 2016 | Phase 4 |
| NCT04457596 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Seagen Inc. |
Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Invasive Breast Carcinoma|Multifocal Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Synchronous Bilateral Breast Carcinoma
|
January 6, 2021 | Phase 3 |
| NCT00191451 | Eli Lilly and Company |
Breast Cancer
|
April 2004 | Phase 2 |
| NCT04686305 | AstraZeneca|Daiichi Sankyo, Inc. |
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
March 9, 2021 | Phase 1 |
| NCT00309556 | Austrian Breast & Colorectal Cancer Study Group|Amgen|Ebewe Pharma GmbH|Hoffmann-La Roche|Sanofi |
Breast Cancer
|
February 2005 | Phase 3 |
| NCT00876395 | Novartis Pharmaceuticals|Novartis |
Breast Cancer
|
September 10, 2009 | Phase 3 |
| NCT00923299 | Institut du Cancer de Montpellier - Val d´Aurelle |
Pancreatic Cancer
|
December 2008 | Phase 1|Phase 2 |
| NCT01152606 | Hoffmann-La Roche |
Breast Cancer
|
August 30, 2007 | |
| NCT00430001 | Danish Breast Cancer Cooperative Group|Hoffmann-La Roche|Sanofi |
Breast Cancer
|
May 2005 | Phase 3 |
| NCT00041470 | University of Washington|Amgen|Bristol-Myers Squibb|GlaxoSmithKline |
Breast Cancer
|
March 2001 | Phase 1|Phase 2 |
| NCT02213744 | Merrimack Pharmaceuticals |
Breast Cancer|HER2 Positive Breast Cancer
|
July 2014 | Phase 2|Phase 3 |
| NCT02139358 | H. Lee Moffitt Cancer Center and Research Institute|Genentech, Inc. |
Breast Cancer
|
September 5, 2014 | Phase 1|Phase 2 |
| NCT00724360 | Nantes University Hospital |
Relapsed+Refractory Leukemia
|
November 2006 | Phase 2 |
Appearance
Solid
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Sliwkowski MX, et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70.
- [2] Hudis CA, et al. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51.
- [3] Barok M, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007 Jul;6(7):2065-72.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.